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Background: Complete revascularisation in patients with multivessel disease who are treated with primary
percutaneous coronary intervention (PPCI) may improve outcomes compared with an infarct-related artery
(IRA)-only strategy. However, non-IRA percutaneous coronary intervention (PCI) may result in additional
myocardial infarction (MI).
Objectives: To determine whether or not in-hospital complete revascularisation was associated with
increased total infarct size (IS) in patients participating in the Complete versus Lesion-only PPCI trial (CvLPRIT).
Secondary objectives were to assess whether or not myocardial salvage index, myocardial ischaemia and final
IS at follow-up were different with a complete revascularisation versus an IRA-only strategy.
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Design: Multicentre, prospective, randomised, controlled and open-label trial with blinded end-point analysis.
Setting: Seven PPCI centres in England, UK.
Participants: ST-segment elevation MI (STEMI) patients with multivessel disease (angiographic stenosis
> 70% in one view or > 50% in orthogonal views) presenting within 12 hours of symptom onset and
treated with the PPCI. Coronary artery bypass surgery, cardiogenic shock and contraindications to
cardiovascular magnetic resonance (CMR; substudy only) imaging were exclusions.
Interventions: Patients were randomised to either complete in-hospital revascularisation or an
IRA-only strategy.
Main outcome measures: The primary outcome was IS as measured by CMR undertaken at 48–72 hours
post PPCI. Secondary outcome measures included microvascular obstruction, myocardial salvage index,
left ventricular volumes and ejection fraction and final IS on the acute and follow-up CMR carried out at
9 months post STEMI.
Results: Patients were recruited from May 2011 until May 2013 and followed up for 12 months.
Of 296 patients randomised in the main CvLPRIT, 205 consented to participate in the CMR substudy and
203 had analysable images for the primary end point. Patients in the IRA-only group (n= 105) were well
matched to those in the complete revascularisation group (n= 98) for all baseline characteristics {mean age
64.1 years [standard deviation (SD) 10.8 years] vs. 63.1 years (SD 11.3 years); male sex 89% vs. 79%,
respectively}. Total IS was not significantly different in the IRA-only and complete revascularisation groups
{median 13.5% [interquartile range (IQR) 6.2–21.9%] of left ventricular (LV) mass vs. median 12.6% (IQR
7.2–22.6%) LV mass, respectively; 95% confidence interval –4.09% to 31.17%; p= 0.57}. Myocardial
salvage index was also not significantly different in the IRA-only and complete revascularisation groups
[median 58.5% (IQR 32.8–74.9%) vs. median 60.5% (IQR 40.6–81.9%), respectively; p= 0.14]. The
prevalence of non-IRA MI on acute CMR was higher in the complete revascularisation group than in the
IRA-only group (22/98 vs. 11/105, respectively; p= 0.02). There was no difference in total IS, ischaemic
burden or LV volumes between treatment groups at follow-up CMR.
Limitations: The CMR substudy population may not be a true representation of the overall study
population. The optimal timing of CMR to measure IS post PPCI is uncertain. Myocardial salvage was
assessable in only 70% of patients.
Conclusions: Multivessel PCI, compared with an IRA-only revascularisation, in the setting of STEMI led to a
small increase in CMR imaging-detected non-IRA MI, but total IS was not increased.
Future work: Larger studies are required to (1) confirm that death and MI are reduced by a complete
revascularisation strategy; (2) assess whether or not functional assessment of non-IRA lesions results in
similar outcomes to a pragmatic angiographic-based revascularisation strategy; and (3) assess the timing of
in-hospital versus staged outpatient complete revascularisation.
Trial registration: Current Controlled Trials ISRCTN70913605.
Funding: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical
Research Council and National Institute for Health Research (NIHR) partnership. The main CvLPRIT was
funded by the British Heart Foundation (SP/10/001) with support from the NIHR Comprehensive Local
Research Networks.
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Plain English summary
Specialist heart doctors increasingly treat patients who suffer large heart attacks as a matter of urgencywith a procedure performed under local anaesthetic. The blocked blood vessel (artery) that causes the
heart attack is opened by inserting a small metal scaffold (stent) at the blockage to hold the artery open.
Up to 50% of patients treated in this way also have other narrowed, but not totally blocked, heart arteries.
Two recent studies in patients with heart attacks and multiple narrowed arteries have suggested that
treating all of the narrowed arteries may be better than just treating the blocked artery. However, there is
concern that the longer procedure, and putting in more stents, may cause more damage to the heart. We
studied 203 patients having a heart attack who were randomly assigned to have only the blocked artery
(105 patients) or all the narrowings treated (98 patients) in seven hospitals in England. We assessed the
amount of heart muscle damage that occurred using magnetic resonance imaging. Patients were more
likely to have more than one area of heart muscle damage if all of their heart arteries were treated than if
only the blocked artery was treated (22% vs. 11% of patients). However, the percentage of the heart that
was damaged was not increased (12.6% vs. 13.5%) and the heart function 3 days and 9 months after
treatment was similar with both treatments. The results of this study provide reassurance that specialists
treating patients with a heart attack can open more than one narrowed artery without increasing the total
amount of heart damage.
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Scientific summary
Background
Multivessel coronary artery disease is seen in approximately 30–50% of patients presenting with
ST-segment elevation myocardial infarction (STEMI) who are treated with the primary percutaneous
coronary intervention (PPCI). Clinical guidelines recommend percutaneous coronary intervention (PCI) to
the infarct-related artery (IRA) only, largely based on registry data that have suggested increased risk
of adverse events with complete revascularisation in those patients selected to receive complete
revascularisation. However, two recent prospective randomised controlled trials [PReventative Angioplasty
in Myocardial Infarction (PRAMI) trial and Complete versus Lesion-only PPCI Trial (CvLPRIT)], which
compared a strategy of complete versus IRA-only revascularisation in the PPCI patients with multivessel
disease, found a reduction in major adverse cardiovascular events with complete revascularisation.
However, there is concern that PCI to non-IRAs may be associated with additional procedural-related
myocardial infarction (MI) that cannot be detected by conventional enzymatic markers at the time of
the PPCI.
Objectives
The primary aim of the current prespecified substudy of the CvLPRIT was to assess whether or not a
complete revascularisation strategy, because it causes additional infarcts in the non-IRA territories, was
associated with greater infarct size (IS) than an IRA-only strategy. Secondary objectives were to assess
whether or not myocardial salvage, microvascular obstruction (MVO), myocardial ischaemia, left ventricular (LV)
volumes and ejection fraction, and final IS at follow-up were different in the two treatment groups.
Design
Pragmatic, prospective, multicentre, randomised, open-label trial with blinded end-point analysis.
Methods
Study population
Patients presenting within 12 hours of symptom onset and being treated by the PPCI for STEMI at
hospitals in seven centres (Leicester, Leeds, Southampton, Harefield, Royal Derby, Kettering and
Bournemouth) were potentially eligible.
Participants
Patients aged ≥ 18 years with multivessel coronary artery disease (angiographic stenosis > 70% in one
view or > 50% in orthogonal views) on baseline angiography were eligible for inclusion. Exclusion criteria
were (1) any contraindication to the PPCI (presentation timing, inadequate arterial access, etc.); (2) age
< 18 years; (3) contraindication to multivessel PPCI, according to operator judgement (with documentation
of reasons); (4) previous Q-wave MI; (5) cardiogenic shock; (6) ventral septal defect or moderate/severe
mitral regurgitation; (7) known severe chronic renal disease (i.e. stage 4 or 5); (8) patients with previous
coronary artery bypass graft; (9) suspected or confirmed thrombosis of a previously stented artery; (10) only
significant non-IRA lesion is a chronic total occlusion; and (11) contraindications to cardiac magnetic
resonance (CMR) imaging (e.g. pacemaker, implantable cardiac defibrillator, implanted stimulators or other
devices and severe claustrophobia) were exclusions.
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Consent and randomisation
Prior to coronary angiography, patients were asked to provide verbal assent for the study, after being read
a short information sheet. Patients who were still eligible after coronary angiography were asked to
confirm their assent. Randomisation was undertaken while the PPCI was being undertaken via a 24-hour
automated voice-activated central system with concealment of treatment allocation. Randomisation was
stratified by infarct location (anterior/non-anterior) and symptom onset (≤ or > 3 hours). When patients
were clinically stable they were given the patient information leaflet to read and those agreeing to
continue participation provided written informed consent.
Interventions
Patients were randomised to one of two groups in a 1 : 1 ratio: complete revascularisation (including all
non-IRAs) or IRA-only treatment. The PPCI was undertaken in accordance with current guideline
recommendations and operators’ routine practice, and could include aspiration thrombectomy, heparin,
bivalirudin or a glycoprotein IIb/IIIa inhibitor. Drug-eluting stents were recommended for both IRA and
non-IRA lesions unless clinically contraindicated, to reduce risk of in-stent restenosis. It was mandated that
if randomised to complete revascularisation, then the IRA be treated first. If there were no clinical
contraindications complete revascularisation was recommended at the same sitting to reduce multiple
vascular punctures, to avoid prolonged hospitalisation and attenuate potential patient drop-out. If the
operator decided for clinical reasons that the procedure be staged, it was mandated that the non-IRA be
treated during index admission.
Cardiac magnetic resonance assessments
The CMR imaging protocols were standardised at hospitals and performed acutely (days 1–4 post PPCI) on
1.5-T scanners and at 9 months’ follow-up. Patients from Derby and Kettering were scanned at
Leicester. The acute CMR scan was recommended on days 2 or 3 post STEMI but always after complete
revascularisation had been performed, if applicable. The baseline scan incorporated functional oedema
(T2-weighted images) and infarct assessment with late gadolinium enhancement (LGE) following 0.2 mmol
of gadolinium diethylenetriaminepentaacetate (Magnevist, Bayer, Faversham, UK) covering the entire left
ventricle. The follow-up scan was similar to the baseline scan with the omission of oedema imaging and
the addition of adenosine stress and rest myocardial perfusion to assess myocardial ischaemia. CMR scans
were analysed at the University of Leicester core laboratory, which was blinded to all patient details and
treatment allocation.
Outcome measures
Primary
Cardiac magnetic resonance imaging measured total IS on LGE images (as a percentage of LV mass) on the
acute CMR scan.
Secondary
Myocardial salvage index (acute and final), the extent of MVO, LV volumes and ejection fraction (acute and
follow-up), ischaemic burden and new (post-index MI) myocardial injury (follow-up) were secondary
outcome measures. Clinical major adverse cardiovascular events (MACEs) were also measured at
12 months.
One hundred patients in each arm had 81% power to detect a 4% absolute difference in IS, assuming a
mean of 20% of LV mass and standard deviation (SD) of 10%, using a two-tailed test with α= 0.05.
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Results
Of the 296 patients randomised in the main CvLPRIT, 205 consented to participate in the CMR imaging
substudy. Of these, two patients were excluded: one patient did not complete the early CMR imaging and
in one patient the LGE images for the primary end point were not analysable. The IRA-only (n= 105) and
complete revascularisation (n= 98) groups were well matched for baseline characteristics {age, 64.1± 10.8
vs. 63.1± 11.3 years; male sex, 89% vs. 79%; time from symptom onset to the PPCI, median 172 minutes
[interquartile range (IQR) 127–268 minutes] vs. median 192 minutes (IQR 131–302 minutes); anterior MI,
36% vs. 35%; respectively}, with no statistically significant differences between groups.
Acute cardiac magnetic resonance
Acute CMR imaging was undertaken at a median of 3 days post PPCI in both treatment arms. There was
no statistical difference in the primary end point of total IS between the IRA-only (13.5%, IQR 6.2–21.9%)
and complete revascularisation groups (12.6%, IQR 7.2–22.6%) of the LV mass [95% confidence interval
(CI) –4.09% to 31.17%; p= 0.57]. The prevalence of multiple territory infarcts in the complete
revascularisation group was double that in the IRA-only group (22/98 vs. 11/105; p= 0.02) and the
number of acute non-IRA infarcts was increased threefold in those undergoing complete revascularisation
(17/98 vs. 5/105; p= 0.004). Acute non-IRA infarcts were generally small, with only 6 of 17 patients in
the complete revascularisation group (median 2.5%, IQR 0.54–4.5%) and two out of five patients in the
IRA-only group (median 2.1%, IQR 0.81–4.5%) having infarcts greater than 4% of LV mass. MVO was
present in more than half of all patients, although quantitatively the amount was very low (median < 0.2%
of the LV mass) and there was no significant difference between groups. In 52 patients (26%), oedema
images were non-diagnostic [no artefact but no oedema discernible (n= 33), not performed owing to
arrhythmia or suboptimal breath-holding (n= 14) or severe artefact (n= 5)]. Area at risk [mean 32.2%
(SD 11.8%) vs. mean 36.0% (SD 12.9%) LV mass; p= 0.06] and the myocardial salvage index (median
58.5%, IQR 32.8–74.9% vs. median 60.5%, IQR 40.6–81.9%) were lower, but not significantly, in the
complete revascularisation group. LV volumes, mass and ejection fraction were similar in both groups.
Follow-up cardiac magnetic resonance imaging
Follow-up CMR imaging was completed in 84 patients in the complete revascularisation group and
80 patients in the IRA-only group. Thirty-nine patients did not undergo repeat CMR: 29 patients declined,
three had died, two cited claustrophobia, one had an implantable cardioverter defibrillator and one had a
severe non-cardiovascular illness; logistical reason accounted for failure to repeat CMR in three patients.
Three patients were unable to undertake adenosine stress perfusion because of obstructive airways disease
(one in the complete revascularisation group and two in the IRA-only group) and perfusion imaging was
not analysable in two patients owing to severe persisting dark-rim artefacts (one in each group). LV
volumes and function were similar between groups [ejection fraction: mean 50.8% (SD 8.7%) vs. mean
49.7% (SD 9.4%); p= 0.42]. The prevalence of infarct and multiple infarcts was greater in the complete
revascularisation group than in the IRA-only group (9/80 vs. 20/84, respectively; p= 0.035). However,
there was no significant difference in total IS between the complete revascularisation group and the
IRA-only group [median 7.3% of LV mass (IQR 3.0–14.4%) vs. median 7.6% (IQR 3.2–15.1%), respectively]
or in final myocardial salvage index. Reversible perfusion defects were seen in 21% of patients in both
groups and overall ischaemic burden was small [complete revascularisation group: mean 3.4% of LV mass
(SD 8.9%); IRA-only group: mean 4.3% of LV mass (SD 11.3%)]. When the extent of ischaemia was
assessed only in patients with defects, the ischaemic burden was not statistically different between the
complete revascularisation and IRA-only groups.
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Clinical outcomes
Median follow-up was 372 days (IRA group: 377 days; complete revascularisation group: 366 days;
p= 0.38). A total of 198 (98%) patients attended the 12-month clinical follow-up (three patients died
before this time point and two patients withdrew consent). The length of inpatient stay and incidence of
in-hospital clinical events were similar in the two treatment arms. There was a borderline significant
reduction in MACEs in patients undergoing complete revascularisation (8/103, 8%) versus IRA only
(18/95, 17.1%), and the corresponding events rates and hazard ratio (0.43, 95% CI 0.18 to 1.04;
p= 0.055) were similar to that seen in the main trial.
Limitations
The CMR substudy population may not be a true representation of the overall study population and the
study was not powered to detect differences in clinical outcomes. The mean IS was slightly lower than
expected and the power of the study was reduced to detect a 4% difference in IS. The optimal timing of
CMR imaging to measure IS post PPCI is uncertain. Myocardial salvage was assessable in only 70%
of the patients.
Conclusions
The CvLPRIT-CMR is the first detailed substudy of acute and follow-up CMR imaging outcomes in a
randomised study of IRA only versus complete revascularisation in patients presenting with STEMI who
have multivessel coronary disease at the PPCI. The data showed that non-IRA PCI is associated with
additional infarction. However, these additional infarcts were relatively infrequent, generally small, and did
not lead to an increase in total IS or a reduction in myocardial salvage index. There is mounting evidence
from randomised trials that treating multivessel disease with complete revascularisation leads to a
reduction in MACEs after the PPCI compared with an IRA-only strategy. The current results provide
reassurance that complete revascularisation does not lead to increased total IS and adds to the evidence
base suggesting in-hospital non-IRA PCI can be undertaken after the PPCI.
Recommendations for research
Larger clinical trials in patients with multivessel disease presenting for the PPCI are required to assess
(1) whether or not death and MI are reduced by a complete revascularisation strategy; (2) whether or not
functional assessment of non-IRA lesions results in similar outcomes to a pragmatic angiographic-based
revascularisation strategy; (3) the optimal timing of in-hospital versus staged outpatient complete
revascularisation; and (4) the cost-effectiveness of various complete revascularisation strategies versus an
IRA-only strategy. In addition, long-term follow-up of patients in the CvLPRIT-CMR imaging substudy
should be undertaken to ascertain whether or not the increase in non-IRA MI associated with adverse
clinical outcomes.
Trial registration
This trial is registered as ISRCTN70913605.
Funding
This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a Medical Research
Council and National Institute for Health Research (NIHR) partnership. The main CvLPRIT was funded
by the British Heart Foundation (SP/10/001), with support from the NIHR Comprehensive Local
Research Networks.
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Chapter 1 Introduction
Treatment of ST-segment elevation myocardial infarction
ST-segment elevation myocardial infarction (STEMI) results from complete occlusion or critically impaired
flow in a main epicardial coronary artery or one of its side branches, deemed the infarct-related artery
(IRA). There are more than 100,000 STEMI presentations in the UK each year.1 The key goal of treatment is
to open the blocked coronary artery, to limit myocardial necrosis and subsequent left ventricular (LV)
dysfunction, which is a key determinant of prognosis.2 The primary percutaneous coronary intervention
(PPCI) is the preferred revascularisation strategy in STEMI.3,4
Multivessel disease at ST-segment elevation myocardial
infarction
Multivessel coronary artery disease (MVD) is typically defined as the presence of ≥ 70% stenosis in ≥ 1
non-IRA. MVD occurs in 28–67% of patients with STEMI and is an independent predictor (IP) of short- to
medium-term prognosis, as summarised in Table 1.5–10 The presence of a chronic total occlusion in the
non-IRA confers a particularly poor prognosis and was an IP of mortality and reduction in LV ejection
fraction (LVEF) post STEMI after correcting for baseline risk profile and cardiogenic shock.11
TABLE 1 Key studies investigating the prognostic importance of MVD in STEMI
Study Year
Number of
participants
in study Main findings Mean follow-up
Tarantini5 2010 288 MVD IP of non-fatal MI (OR 5.7), combined death/MI (OR 4.8)
and combined MACEs (OR 4.7). MVD also IP for LV
remodelling (OR 2.2)
32 months
Dziewierz6 2010 1598 MVD IP (HR 1.58) for mortality at 12 months in a model
including left anterior descending artery IRA, Killip class
12 months
Corpus7 2004 820 Significantly higher non-fatal MI, target vessel revascularisation,
mortality, MACEs at 30 days in MVD. MVD IP of mortality at
12 months (OR 3.3) in model including age, renal function
and LVEF
12 months
Sorajja8 1997 2082 Increasing composite MACEs at 12 months with number of
diseased vessels. MVD strongest IP for MACEs (HR 1.9) and
mortality (HR 2.6)
12 months
Jaski9 1992 151 MVD only IP for prediction of angioplasty success (MVD 75%
vs. single vessel disease 92%; p < 0.005) on stepwise
logistic regression
Inpatient
Muller10 1991 236 Reduced LVEF and increased mortality in MVD group. MVD
strongest IP of inpatient mortality in model including LVEF, age,
TIMI post lysis
Inpatient
HR, hazard ratio; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular event; MI, myocardial
infarction; OR, odds ratio; TIMI, thrombolysis in myocardial infarction; TVR, target vessel revascularisation.
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Management of multivessel disease in patients presenting with
ST-segment elevation myocardial infarction
Current guidelines
The guidelines from the European Society of Cardiology (ESC)3 and American Heart Association (AHA)4
recommend percutaneous coronary intervention (PCI) of the IRA only at the PPCI unless the patient is in
cardiogenic shock, where complete revascularisation (CR) is permitted for critical (> 90% stenosis) or
unstable lesions (ESC/AHA: class IIa, level of evidence B). The two alternative options at the PPCI are CR
during the index admission (of all significant lesions, including in non-IRAs) and planned outpatient PCI of
the non-IRA at a later date (usually < 6 weeks) as a staged procedure.12 Where outpatient revascularisation
to non-IRAs is being considered, this should be preceded by non-invasive ischaemia assessment [e.g.
myocardial perfusion scintigraphy (MPS), stress cardiovascular magnetic resonance imaging (MRI)] (ESC:
class I, level of evidence A; AHA: class IIa, level of evidence B).3,4 Fractional flow reserve (FFR) assessment of
non-IRAs at the PPCI is not currently undertaken as it is felt that potential microvascular dysfunction in
non-IRA territories could render FFR inaccurate. However, one study has investigated this and showed that
FFR at the PPCI was unchanged when reassessed 35 days later (FFR 0.77 at both time points), suggesting
that non-IRA lesion severity may be accurately measured by FFR in acute STEMI.13 The resulting lack of
consensus regarding management of MVD at the PPCI was reflected by the US Cardiovascular Data
Registry, demonstrating wide variation in practice, with 0–38% of MVD patients undergoing CR at the
PPCI on registry studies.14,15
Evidence base for revascularisation strategies for multivessel disease at
primary percutaneous coronary infarction
At the time of this grant application (July 2010) the evidence base for the management of MVD at the
PPCI was weak, largely based on retrospective analyses and registries.3,4 There were only a small number of
randomised clinical trials, with clinical outcomes that were of limited quality, lacking statistical power, and
with varying design and outcomes (Table 2).
TABLE 2 Randomised trials of CR vs. IRA-only PPCI
Trial Design Year
Mean
follow up
Favoured
strategy Findings Comment
Di Mario16 IRA only, n= 17;
CR, n= 69
2002 1 year ↔ No MACE difference.
Trend to less repeat
revascularisation
with CR (CR 17%
vs. IRA-only 35%;
p= 0.247).
Equivalent costs
Study powered on
basis of cost efficacy
calculation; unequal
randomisation
Politi17 Immediate CR
(n= 65), staged
CR (n= 65) and
IRA only (n= 84)
2003–7 2.5 years CR MACE: 50.0% CR,
20.0% staged CR and
immediate CR 23.1%;
p< 0.001; HR ≈0.4.
MACE driven by
revascularisation
Unequal groups
Low antiplatelet use
in complete group
Ghani18 CR (n= 80) and
IRA only (n= 41)
2012 3 years ↔ MACEs 35% in
both groups
Reduced re-PCI
in complete
Wald19 CR (n= 234)
and IRA only
(n= 231)
2013 23 months CR MACEs 9% in CR,
23% in IRA; HR 0.34
Reduced MI and
refractory angina
↔, no significant difference; HR, hazard ratio; MACE, major adverse cardiac event.
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By far the best-quality study to date is the Preventative Angioplasty In Myocardial Infarction (PRAMI) trial,
the results of which were published in August 2013,19 at which time the Complete versus Lesion-only
PRimary percutaneous coronary Intervention Trial (CvLPRIT) was in follow-up. This trial demonstrated an
extremely large reduction [hazard ratio (HR) 0.35, 95% confidence interval (CI) 0.21% to 0.58%;
p< 0.001] in major adverse cardiovascular events [MACEs; death from cardiac causes, non-fatal myocardial
infarction (MI) or refractory angina], which was driven by all components of the primary end point.19
However, the trial could be criticised for randomising patients after the PPCI, potentially introducing
selection bias, and an excess of anterior MI in the IRA-only arm and the inclusion of the ‘soft’ end point of
refractory angina in the primary outcome. The benefits of a CR strategy remained in doubt, particularly
with concern over the safety of such a strategy undertaken at same sitting as the PPCI.
Potential risks and benefits of a complete revascularisation
strategy at primary percutaneous coronary intervention
Potential benefits
A CR strategy at the time of the PPCI in STEMI patients with MVD may:
1. Limit infarct size (IS) and increase the amount of salvaged myocardium by increasing collateral flow to
the at-risk, but non-necrotic, peri-infarct zone. There are no specific data (either observational or from
clinical trials) available to confirm such a benefit.
2. Reduce overall hospital stay and total cost of care.
3. Reduce ischaemic burden,20 which appears to be an important determinant of outcome following MI,
at least in the era before the PPCI.21
4. May reduce further PCI at a later date, either for symptoms or silent ischaemia as per current
guidelines,3,4 reducing subsequent hospitalisation for the patients and with resultant economic benefits.
5. Reduce the risk of recurrent MI/death, as has been observed for non-STEMI,22 although this finding
has not been replicated in chronic stable angina.23
6. Reduce vascular complications by having all PCI performed during the index intervention through a
single-access site.
Potential risks
Potential risks of a CR strategy are detailed below.
1. IS may be increased. Approximately one-third of patients undergoing even seemingly uncomplicated
elective PCI experience a rise in troponin levels consistent with the diagnosis of myocardial necrosis.24
The risk for unstable angina patients is higher, with 53% experiencing a post-PCI troponin elevation.24
There is debate whether or not such troponin increases are of independent prognostic significance.25
The mechanisms of injury are likely to include necrosis of myocardial tissue adjacent to stent insertion
and microembolisation to the distal vasculature.26 IS in the 30% of patients with new infarction was
5% of LV mass (LVM) and 1.3% of LVM for the entire cohort.26 In a mixed cohort of patients
undergoing elective PCI (n= 92) or coronary artery bypass grafting (n= 60), those who experienced
new myocardial injury, detectable on cardiac magnetic resonance (CMR) imaging, had a threefold
increase in MACEs.27 There is also the not insignificant, but impossible to quantify, risk of complete
no-reflow in the non-IRA which could have devastating consequences in a patient undergoing the PPCI.
There are no data available that tell us the frequency of ‘new’ injury in the non-IRA with multivessel
PPCI, but we can anticipate this will be significantly higher than in patients undergoing elective PCI.24
Even without myocardial necrosis, resting perfusion28 and myocardial perfusion reserve29 are reduced
following PCI, potentially impairing collateral flow to the area at risk (AAR) and decreasing the amount
of salvaged myocardium.
2. Contrast-induced nephropathy, as a result of the increased volume load of contrast, could be increased.
3. Stenting of bystander lesions in the non-IRAs which are neither causing ischaemia nor symptoms may
lead to no symptomatic or prognostic benefit to the patient and with increased costs to the NHS.
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4. There may be an increased risk of both early, especially in the thrombogenic milieu of acute infarction,
and late stent thrombosis and restenosis.
5. Non-IRA revascularisation may not reduce ischaemia more effectively than by intensive medical therapy
following MI.30
Rationale for Complete versus Lesion-only PRimary
percutaneous coronary Intervention Trial cardiac magnetic
resonance imaging
Prognosis following acute myocardial infarction
Left ventricular systolic dysfunction has long been recognised as an important sequelae in survivors of MI.2
In 605 male survivors of acute MI, LVEF, LV end-diastolic volume (LVEDV) and LV end-systolic volume
(LVESV) were all predictive of mortality during an average of 78 months’ follow-up, but only LVESV was an
IP on multivariate analysis.2 The importance of reductions in ejection fraction, IS and increases in LV
volumes have been confirmed in over 2300 survivors of STEMI receiving reperfusion therapy.31 Limiting IS
with reperfusion leads to improved LV function and attenuation of subsequent cardiac remodelling
(LV dilatation > 20%), and is a key aim of current treatment strategies in STEMI.
Cardiac magnetic resonance imaging assessment of myocardial injury
following ST-segment elevation myocardial infarction
Cardiac MRI is the gold standard technique for the quantification of LV volumes and function and late
gadolinium enhancement (LGE) imaging can detect and quantify MI with unique precision.32,33 In a dog
model of experimental reperfused MI, microvascular obstruction (MVO) and IS were strongly related to
early LV remodelling (r= 0.89 and r= 0.81, respectively).34 MVO was the best IP (r2= 0.71; p< 0.001) of
remodelling.34 In patients, CMR-measured MVO correlates strongly with ST-segment resolution in patients
undergoing the PPCI but relatively weakly with myocardial blush grade and not significantly with
thrombolysis in MI (TIMI) flow.35 However, CMR-measured MVO is not simply an oversensitive measure of
small vessel obstruction. Larger infarcts on CMR are consistently associated with larger ventricular volumes,
reduced ejection fraction and increased MVO, which occurs in 40–60% of patients treated by the PPCI.35–37
IS and MVO have consistently been related to adverse ventricular remodelling. In all the PPCI studies in
which MVO has been included in a multivariate model, MVO predicts remodelling independently of IS,
ejection fraction and cardiac volumes.35,36,38–40
Prognostic value of cardiac magnetic resonance imaging following primary
percutaneous coronary intervention
Infarct size and MVO have been shown to be related to medium-term prognosis, even in relatively small
studies. For example, in 122 patients with STEMI undergoing the PPCI, LVEF, LVEDV and LVESV were
all associated with IS (r= –0.75, r= 0.42 and r= 0.69, respectively; all p< 0.001) and outcome. IS on CMR
was the only IP of MACEs (one death, one MI and 16 heart failure admissions) at 2 years.40 In 184 patients
undergoing successful PPCI, the presence of MVO on CMR was independently predictive of MACEs
(five deaths, 13 heart failure, 18 re-infarction and eight unstable angina) at 1 year.40 Larger studies have
consistently shown that IS and MVO are independently related to prognosis, even when other clinical
variables, and LV volumes and ejection fraction are considered.41–43
Myocardial salvage index
The extent of myocardial necrosis after an acute coronary occlusion is variable and dependent on a
number of factors including the time to reperfusion, collateral blood flow, metabolic demand of the tissue
and the total AAR, as determined by amount of tissue that is acutely hypoperfused at the time of coronary
artery occlusion, probably being the most important.44 The efficacy of reperfusion strategies can be
assessed by calculating myocardial salvage index (MSI) (AAR IS/AAR), which may be an important measure
of outcome.45
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Cardiac magnetic resonance imaging and myocardial salvage index
Cardiac MRI can accurately quantify MSI. During ischaemia or infarction, myocardial tissue develops
oedema that can be detected as high signal intensity on T2-weighted (T2W) images, and the area of
oedema is greater than the area of irreversibly damaged, necrotic myocardium.46,47 Myocardium with high
T2 signal closely correlates with the AAR, confirmed in experimental models of both reperfused48 and
non-reperfused MI.49 As expected, the size of salvaged myocardium decreases with increased IS, as
measured by CMR imaging.46 Two small clinical studies have validated the MSI with CMR imaging against
single-photon emission computed tomography (SPECT).50,51 A major advantage of CMR imaging-measured
salvage index is that it can be measured during a single examination in addition to quantification of
volumes, function, IS and MVO. Although black-blood T2W imaging has been prone to artefact, recent
advances including increased slice thicknesses, use of coil signal intensity correction algorithms and motion
correction have made the assessment of oedema much more robust.45
Summary
Cardiac MRI offers a unique and robust assessment of the success of revascularisation for STEMI. CMR
imaging infarct characteristics are the best proven surrogate markers of medium-term outcome in patients
with STEMI treated by the PPCI. It was aimed, by embedding CMR imaging in the main CvLPRIT, to have a
more robust assessment of the differences in the efficacy and safety of the revascularisation strategies being
tested that could only be seen with a much larger population if there was reliance on clinical outcomes
alone. Another aim was to obtain a greater understanding of the mechanisms by which differences in
outcome between the two groups may result. The risk of new MI from PCI to the non-IRA’s during the PPCI
and the effect on myocardial salvage and subsequent ventricular remodelling and medium-term outcome
could be established for the first time through the use of CMR imaging in this trial population.
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Chapter 2 Research objectives
The original research objectives of the CvLPRIT-CMR imaging substudy were to assess whether or not:
1. IS, MSI and the extent of MVO are different in the CR versus IRA-only strategies.
2. A CR strategy in STEMI patients with MVD results in altered LV volumes and function in the medium
term (9 months post MI).
3. Reducing ischaemic burden post STEMI by CR is associated with altered medium-term outcome
(death, MI, hospitalisation for heart failure/angina).
Primary hypothesis
l IS (% LVM) will be increased in the CR versus IRA-only group.
Secondary hypotheses
l MSI will be reduced in the CR versus IRA-only group.
l The extent of MVO will be increased and ejection fraction will be decreased in complete versus
IRA-only patients.
l A CR strategy will reduce ischaemic burden more than an IRA-only strategy, but will not be associated
with reduced MACEs at the 1-year follow-up.
l New (post-index MI) myocardial injury (CMR imaging detected) will be increased in patients having
further PCI compared with those managed with culprit-only PPCI and optimal medical therapy.
DOI: 10.3310/eme03010 EFFICACY AND MECHANISM EVALUATION 2016 VOL. 3 NO. 1
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McCann et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7

Chapter 3 Methods
Study overview
Study design
The CvLPRIT was a multicentre, open, randomised controlled clinical trial comparing inpatient IRA-only
and CR for the management of MVD at the PPCI for STEMI. The trial was funded by the British Heart
Foundation (BHF) in 2010, as a pilot study aiming to recruit 250 patients in four centres (Leicester, Leeds,
Harefield and Southampton). The embedded CMR imaging substudy (CvLPRIT-CMR) was funded by the
Efficacy and Mechanism Evaluation (EME) programme, a Medical Research Council (MRC) and National
Institute for Health Research (NIHR) partnership, following a fast-track application in August 2010. The
design was a pragmatic, multicentre, prospective, randomised controlled, open, clinical trial with blinded
end-point (CMR imaging) analysis (PROBE design).52 It was intended to complete recruitment, follow-up
and data analysis within 2 years of study initiation.
Participants
Patients presenting to the participating centres with acute STEMI and MVD being treated by the PPCI.
Participating centres and recruitment dates
Recruitment started in May 2011 and was slower than anticipated. The study was rolled out to three
additional centres with support from the NIHR Comprehensive Local Research Networks. The BHF awarded
a 1-year extension in 2013 to allow the recruitment target to be extended (285 patients, ensuring) and
the 12-month follow-up to be completed. The NIHR EME also awarded a 9-month time extension with a
small cost extension. The participating hospitals and recruitment dates are given below.
The seven centres undertaking 24/7 PPCI in this multicentre study were:
1. Glenfield Hospital (recruited May 2011–April 2013).
2. Southampton General Hospital (recruited August 2011–April 2013).
3. Leeds General Hospital (recruited September 2011–April 2013).
4. Harefield Hospital (recruited November 2011–April 2013).
5. Kettering General Hospital (recruited July 2012–April 2013).
6. Royal Derby Hospital (recruited August 2012–April 2013).
7. Royal Bournemouth Hospital (recruited February 2013–April 2013).
Inclusion criteria
1. Suspected acute STEMI: ST-segment elevation (≥ 2mm in two or more adjacent chest leads, ≥ 1mm in
two or more adjacent limb leads, ≥ 1mm in leads V7–V9) or left bundle branch block (LBBB) on 12-lead
electrocardiography (ECG).
2. Symptom duration < 12 hours.3,4
3. Scheduled for the PPCI.
4. Verbal assent followed by written informed consent.53
5. MVD: defined as IRA plus ≥ 1 non-IRA with significant disease (> 70% stenosis in one plane or > 50%
in two planes). The non-IRA must be a stentable epicardial coronary artery or a major branch of > 2 mm
in diameter.53
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Exclusion criteria
l Age < 18 years.
l Clear indication for or against CR according to operator.
l Previous Q-wave MI.
l Previous coronary artery bypass graft (CABG).
l Cardiogenic shock.
l Ventricular septal defect or moderate/severe mitral regurgitation.
l Severe chronic kidney disease [estimated glomerular filtration rate (eGFR) < 30ml/minute].
l Stent thrombosis.
l The only significant non-IRA lesion is a chronic total occlusion.
l Standard MRI contraindications (pacemaker, implantable cardiac defibrillator, intracranial implant
incompatible with magnetic field, severe claustrophobia, weight > 200 kg).
Initial assessment and assent
The coronary care unit at each centre was alerted by paramedics of incoming STEMI patients. On arrival
at hospital, the CvLPRIT research team discussed the study with patients once acute STEMI of < 12 hours’
duration was confirmed on history and ECG. Prior to the PPCI, an ethically approved, short study narrative
was read to the patient (see Appendix 1). Where eligible patients provided verbal agreement (assent) to
enter the randomised controlled trial, this was documented in the medical records. Assent allowed delivery
of key information to patients within expected time constraints during STEMI and sufficient opportunity
for patients to ask questions. Verbal information is understood and retained significantly better by patients
compared with written information in acute MI trials.54–56 The assent procedure was successfully used in
the Strategic Reperfusion Early after Myocardial Infarction (STREAM)57 and the Reperfusion Facilitated
by Local adjunctive therapy in STEMI (ReFLO-STEMI)58 multicentre acute STEMI studies. If patients met the
inclusion criteria after angiography they were asked to give further verbal assent before randomisation.
Randomisation
Patients were randomised on-table, pre PCI, via a dedicated interactive voice recognition telephone service
to either in-hospital IRA-only revascularisation or CR. Randomisation was concealed to all investigators and
stratified using minimisation, by anterior or non-anterior STEMI (ECG-guided), and symptom time (time
to reperfusion) less than or equal to, or greater than 3 hours, as these are strong prognostic indicators post
STEMI.59 Randomisation was run through an independent company (Sealed EnvelopeTM, London, UK) and
took less than 90 seconds.
Consent
Randomised patients were given patient information leaflets within 24 hours, assuming they were
medically fit, and asked to provide full written informed consent to continued study participation, including
the optional CMR imaging substudy. At all times, patients were informed that they were under no
obligation to continue study participation.
Interventions
Infarct-related artery-only revascularisation
The PPCI to the IRA only was regarded as the standard of care and was performed in accordance with the
ESC3 and American College of Cardiology Foundation (ACCF)/AHA4 guidelines. Multiple angiographic
views of the left and right coronary artery systems were acquired in standard radiographic projections
using digital fluoroscopic angiography systems at 15 frames per second.
PeriPCI adjuncts were administered at the operator’s discretion: dual antiplatelet loading with aspirin plus
clopidogrel (Plavix®; Sanofi-aventis Ltd, UK) or prasugrel (Efient®; Eli Lilly and Company Ltd, UK) or
ticagrelor (Brilique®; AstraZeneca, UK) for P2Y12 inhibition pre angiography; heparin, bivalirudin (Angiox®;
Medicines Company, USA), glycoprotein IIb/IIIa inhibitors [e.g. abciximab (ReoPro®; Eli Lilly & Co Ltd, UK)],
METHODS
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thrombus aspiration devices (e.g. Export®; Medtronic, USA), vasodilators [e.g. adenosine (Adenoscan®;
Sanofi-aventis Ltd, UK)] and isosorbide dinitrate (Isoket®; UCB Pharma Ltd, Belgium) during the PPCI.
The choice of stent and stent implantation technique were at the operator’s discretion but drug-eluting
stent (DES) use was strongly encouraged.
Complete revascularisation
Complete revascularisation was the investigational intervention. It was recommended that revascularisation
be completed during the index PPCI procedure (Figure 1). Where this was not possible (at the operator’s
discretion), non-IRA PCI was performed during the index admission, within 36 hours of the PPCI and prior
to CMR imaging.
All patients were treated with optimal medical treatment as per ESC and ACCF/AHA guidelines [dual
antiplatelet therapy (DAPT), angiotensin-converting enzyme (ACE) inhibition, beta blockade, high-dose
statin].3,4 Repeat coronary angiography was recommended only for (1) recurrent ischaemic symptoms with
confirmation on non-invasive imaging (e.g. stress CMR imaging, SPECT) or (2) at the discretion of the local
investigator following a positive non-invasive test at 6–8 weeks post PPCI.
Ethics
The study was conducted in accordance with the Fifth Declaration of Helsinki.60 Trial protocols, patient
information leaflets and consent forms were approved by the National Research Ethics Service and each
site was granted site-specific approval from its NHS Research and Development department before
trial commencement.
History-taking
Patients were interviewed once clinically stable post PPCI to ascertain their past medical history, cardiac risk
factors and medications history. Particular attention was paid to determining the presence or absence of
the following:
l diabetes mellitus (DM)
l hypercholesterolaemia
l hypertension
l prior MI or PCI
l smoking history.
Investigations and analyses
Consenting patients were allocated an anonymised study number allowing blinded CMR imaging analysis.
Investigations performed relevant to the CvLPRIT-CMR substudy are summarised in Table 3.
Angiographic analysis
Pre- and post-PPCI epicardial coronary flow was assessed using TIMI scoring (Table 4).61
The degree of stenosis in each significant IRA and non-IRA lesion was graded visually by local investigators
on a five-point scale (1, 1–49%; 2, 50–74%; 3, 75–94%; 4, 95–99%; and 5, 100%). Additionally, after
CMR analysis had been completed and the database locked, core laboratory angiographic analysis was
performed by a single operator (JNK) to determine (1) collateral flow to the IRA pre PPCI (graded using the
Rentrop system);62 (2) the percentage diameter stenosis of lesions by two-dimensional (2D) quantitative
coronary angiography (QCA) using QAngioXA version 1.0 (Medis, Leiden, the Netherlands) (Figure 2); and
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TABLE 3 Summary and order of investigations
Events Order Time point Investigation
Inpatient 1 Immediately Angiography and the PPCI
Inpatient 2 Pre PPCI Biomarker assessment (creatine, eGFR, CK)
Inpatient 3 90 minutes post PPCI ECG
Inpatient 4 12 hours post PPCI Biomarker assessment (creatinine, eGFR, CK)
Inpatient 5 24 hours post PPCI Biomarker assessment (CK)
Inpatient 6 Pre-discharge History-taking
Inpatient 7 Pre-discharge Acute CMR scan
9-month follow-up 9 9 months post PPCI Follow-up CMR scan
12-month follow-up 11 12 months post PPCI History-taking/case note review
CK, creatine kinase.
TABLE 4 Thrombolysis in MI and Rentrop visual angiographic scoring systems
Perfusion analysed Scoring system Definition
Epicardial coronary flow TIMI flow grade 0 No perfusion: no antegrade flow beyond occlusion
Epicardial coronary flow TIMI flow grade 1 Penetration without perfusion: contrast passes beyond occlusion,
but fails to opacify entire distal coronary bed
Epicardial coronary flow TIMI flow grade 2 Partial reperfusion: contrast passes occlusion and opacifies distal
coronary bed, but rate of entry and exit of contrast slower than in
unaffected vessels (non-IRAs)
Epicardial coronary flow TIMI flow grade 3 Complete reperfusion: contrast passes occlusion and opacifies distal
coronary bed, and rate of entry and clearance of contrast same as in
non-IRAs
Collateral flow to IRA
territory (AAR) pre PPCI
Rentrop grade 0 Absent visible collateral flow
Collateral flow to IRA
territory (AAR) pre PPCI
Rentrop grade 1 IRA side branches only filled
Collateral flow to IRA
territory (AAR) pre PPCI
Rentrop grade 2 Partial filling of main IRA vessel
Collateral flow to IRA
territory (AAR) pre PPCI
Rentrop grade 3 IRA completely filled by collaterals
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(3) the complexity and extent of coronary artery disease (CAD) using the validated SYNTAX score (sum of
SYNTAX scores for each lesion) by two observers (JNK and SAN).63
The percentage diameter stenosis of lesions was assessed by 2D QCA using QAngioXA version 1.0.
The artery diameter is quantified by comparison with the reference catheter (white arrow, here 6 French,
2.0 mm). Loci proximal and distal to the lesion under assessment are manually identified. The software
then automatically contours the artery and lesion. Manual adjustment of contours can be performed if
needed. In Figure 2, the distal right coronary artery lesion (blue arrow) is of 80% stenosis in a segment of
2.4 mm diameter.
Blood sampling
Twenty millilitres of venous blood was collected with the patient lying semirecumbent. For the
assessment of serum creatinine, eGFR and creatine kinase (CK), blood was collected in clot activator tubes
(BD Diagnostics, Oxford, UK) as summarised in Table 3. These were routine clinical bloods analysed using
the Clinical Pathology Accreditation Service (CPA)-accredited (United Kingdom Accreditation Service,
Middlesex, UK) laboratories at each centre, which were to ISO 15189 standard (International Organisation
for Standardisation, UK).
Electrocardiography
A 12-lead surface ECG was taken on arrival of the patient to hospital to confirm STEMI. This was repeated
at 90 minutes post PPCI to assess the degree of ST-segment resolution, and quantified as the sum of
ST-segment elevation at 60 milliseconds after the J-point in the infarct-related leads. ST-segment resolution
was defined as complete (> 70%), partial (30–70%) or absent (< 30%)64 compared with the initial ECG.
Cardiovascular magnetic resonance imaging
Cardiac MRI was performed on 1.5-T scanners (Table 5) as close to 72 hours post PPCI as possible (acute
CMR imaging) during the index admission, and at 9 months (follow-up CMR imaging). CMR imaging was
permitted at 24–48 hours in patients due for weekend discharge, and could be delayed if necessitated by
the patient’s clinical condition and was always performed after additional PCI in CR patients who had
staged procedure to treat the non-IRA(s). Prior to CMR imaging, patients completed a safety questionnaire.
At the 9-month CMR imaging, an additional stress questionnaire was completed to ensure suitability for
adenosine and caffeine abstinence.
TABLE 5 Cardiac magnetic resonance scanners used at the centres
Recruitment centre Centre where CMR imaging performed 1.5-T scanner used
Bournemouth Bournemouth Siemens Avanto (Erlangen, Germany)
Derby, Glenfield, Kettering Glenfield Siemens Avanto (Erlangen, Germany)
Harefield Harefield Siemens Avanto (Erlangen, Germany)
Leeds Leeds Philips Intera (Best, the Netherlands)
Southampton Southampton Siemens Avanto (Erlangen, Germany)
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Acute cardiac magnetic resonance imaging
The detailed protocol for the acute CMR scan is summarised in Figure 3 and explained in subsequent
sections. All imaging was performed with retrospective electrocardiographic gating using dedicated cardiac
receiver coils, unless atrial fibrillation or frequent ectopy was present, or for tagging images, where
prospective gating was used. Parallel imaging (factor 2) was used to shorten breath-holds for all imaging,
except T2W short-tau inversion recovery (T2W-STIR).
Cine imaging
After the acquisition of localising images, balanced steady-state free precession cine imaging (bSSFP) was
performed in four-, two- and three-chamber long-axis views. The field-of-view was optimised to achieve
in-plane spatial resolution of ≈1.1–1.7mm× 1.3–1.9 mm. The number of segments was adjusted
according to heart rate [heart rate < 50 beats per minute (b.p.m.), 17 segments; heart rate 50–70 b.p.m.,
15 segments; heart rate 71–90 b.p.m.; 13 segments; heart rate > 90 b.p.m., 11 segments] at the discretion
of the supervising investigator.
Intravenous contrast was administered before short-axis cine stack acquisition to minimise scans time
before acquiring the LGE images (primary end point). Cine imaging was performed in contiguous short-axis
slices covering the entire left ventricle and right ventricle (Figure 4). The basal short-axis slice was planned
at the mitral valve annulus perpendicular to the interventricular septum to minimise partial volume at the
atrioventricular boundary.
Oedema (area-at-risk) imaging
The AAR was assessed using black-blood T2W-STIR imaging. T2W-STIR imaging was performed using coil
signal intensity correction in four-, two- and three-chamber long-axis views and contiguous short-axis slices
covering the entire left ventricle (Figure 5). Slices 10-mm thick were acquired to optimise signal-to-noise
ratio. The echo train length (ETL) was adjusted with heart rate (heart rate < 50 b.p.m., ETL 40; heart rate
50–70 b.p.m., ETL 30; heart rate 71–90 b.p.m., ETL 25; heart rate > 90 b.p.m., ETL 20).
Late gadolinium enhancement imaging
Late gadolinium enhancement imaging was commenced 10 minutes after intravenous administration of
0.2 mmol/kg gadolinium diethylenetriaminepentaacetate (Gd-DTPA; Magnevist, Bayer, Germany) using
a segmented inversion-recovery gradient-echo sequence with a two-beat trigger. This was preceded by a
bSSFP Look–Locker inversion time (TI) scout to determine the optimal TI to null unaffected myocardium.
The TI was progressively adjusted to maintain nulling of unaffected myocardium. LGE imaging was
performed in four-, two- and three-chamber long-axis views and contiguous short-axis slices covering the
entire left ventricle (Figure 6). T2W-STIR, cine and LGE short-axis images were acquired at identical slice
positions. The number of segments was adjusted with heart rate (heart rate < 50 b.p.m., 40 segments;
heart rate 50–70 b.p.m., 30 segments; heart rate 71–90 b.p.m., 25 segments; heart rate > 90 b.p.m.,
20 segments).
Follow-up cardiac magnetic resonance imaging
The protocol for follow-up CMR imaging was similar to the acute scan, but with oedema (T2W-STIR)
imaging omitted and assessment of reversible ischaemia included with perfusion assessment included.
Perfusion imaging
Stress perfusion imaging was performed following pharmacological vasodilator stress using intravenous
adenosine infusion at 140 µg/kg/minute for 3 minutes. Heart rate and blood pressure and symptoms
were closely monitored during stress at 1-minute intervals. A radiographer was present within the scanner
room with the patient during stress. First-pass perfusion imaging was performed following intravenous
0.1 mmol/kg Gd-DTPA using a breath-hold, saturation-recovery gradient-echo sequence at basal,
mid-ventricular and apical short-axis LV slices, planned as per myocardial tagging. Acquisition was
undertaken every heart beat to optimise visual assessment of contrast wash in. Where the heart rate was
> 110 b.p.m., phase resolution was reduced to 70% to increase temporal resolution. In the rare situation
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where heart rate was > 125 b.p.m., acquisition was undertaken every other heart beat. Rest perfusion
imaging was performed 10 minutes after stress perfusion imaging using identical parameters with further
administration of 0.1mmol/kg Gd-DTPA.
Cardiac magnetic resonance imaging analysis
All quantitative CMR imaging analysis was performed offline, blinded to all patient details and
randomisation, by a single operator (JNK) and supervised by a CMR imaging expert (GPM, 10 years’
experience). Image quality was graded by two observers (JNK and GPM) as summarised in Table 6.
Volumetric analysis
Volumetric analysis was performed using QMass® v7.1 (Medis, Leiden, the Netherlands). LV endocardial
and epicardial borders were manually contoured onto contiguous short-axis cine slices at end-diastole and
end-systole, excluding papillary muscles, trabeculae and epicardial surfaces. This method has superior
reproducibility65 compared with inclusion of papillary muscles and trabeculae in mass assessment. This
allowed calculation of LVEDV, LVESV, LV stroke volume, LVEF and LVM. Volumes and LVM were indexed
for body surface area.
Oedema (area at risk) quantification
Oedema (AAR) was quantified as hyperenhancement on T2W-STIR imaging using CMR imaging40
(Circle Cardiovascular Imaging, Calgary, AB, Canada) using Otsu’s automated threshold (OAT).66
Endocardial and epicardial borders were manually contoured on contiguous LV short-axis slices, excluding
papillary muscles, trabeculae, epicardial surfaces and blood pool artefact (Figure 7).
Otsu’s automated threshold automatically calculates a unique signal intensity threshold for each slice by
dividing the greyscale signal intensity histogram into two groups (enhanced and normal) based on the
threshold giving the least intraclass variance within each group,66 without the need for a user-defined
region of interest (ROI). Oedema was calculated as a percentage area for each of the 16 AHA segments67
(Figure 8). Total AAR was expressed as percentage of LVM. The most apical T2W-STIR slice was excluded
to minimise partial volume.
Two manual corrections were applied to AAR measurements: (1) inclusion of hypointensity within
enhancement corresponding to intramyocardial haemorrhage (IMH);68 and (2) and exclusion of small,
isolated enhanced regions without interslice continuity in non-IRA territories deemed noise artefact
(Figure 9).
TABLE 6 Cardiac magnetic resonance image quality grading scale
Sequence Grade 1.5-T scanner used
All sequences N/A Sequence not performed
0 Non-analysable
1 Minor artefact in ROI that may affect analysis; however,
images analysable
2 Minimal artefact, which does not affect images analysis
3 Good quality, no artefact
Oedema No visible oedema No artefact however no oedema seen (no CNR between
oedema and unaffected myocardium)
N/A, not applicable; ROI, region of interest.
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Late gadolinium enhancement
Infarct was defined semi-automatically on magnitude LGE images using CMR imaging.40 Endocardial and
epicardial borders were manually contoured on contiguous short-axis LV slices, excluding papillary muscles,
trabeculae and epicardial surfaces and the full-width half-maximum (FWHM) technique69 applied. Here, a
2-cm2 ROI was manually drawn in the infarct core and enhancement calculated as pixels of > 50% of the
automatically determined maximum signal intensity in the ROI (Figure 10). Total IS was expressed as a
percentage of LVM and segmental area extent of LGE was calculated.67 The apical LGE slice was excluded
to minimise partial volume effect. Total IS was manually corrected by including hypointensity within
enhancement (MVO) to total IS, and exclusion of noise artefact as per AAR quantification.
Myocardial salvage index quantification
Myocardial salvage index70 was expressed as ‘baseline MSI’ using total IS at acute CMR imaging and
‘final MSI’ using final total IS at follow-up CMR imaging:
AAR− IS
AAR
× 100. (1)
Perfusion analysis
Perfusion images were visually, semiquantitatively assessed for perfusion defects (visible defect for five or
more heartbeats) by the consensus of two experienced observers (JNK and GPM). Stress perfusion, rest
perfusion and LGE images were coregistered to allow accurate assessment based on all available data.
Three perfusion patterns were possible: (1) no perfusion defect – normal perfusion of myocardium during
stress and rest; (2) reversible perfusion defect – perfusion defect seen only during stress perfusion, in
viable, non-infarcted myocardium; and (3) matched perfusion defect – stress perfusion defect in infarcted
myocardium (Figure 11). Perfusion defects and areas of infarction were graded as subendocardial (≤ 50%
transmurality) or transmural (> 50% transmurality) and given a score of 1 or 2, respectively, per segment,
whereas normal myocardium was scored 0. A modified summed difference score was calculated
(maximum score 32),71 defined as the difference between the sum of segmental stress perfusion defects
and LGE.23 The summed difference score was expressed as percentage of the maximum possible to give an
estimate of ischaemic burden (% LVM).72 Examples of no perfusion defect, reversible perfusion defect and
matched defect to IS are shown in Figure 11.
Study outcomes
Primary outcome
The primary outcome of the CMR imaging substudy was total IS (% LVM) on acute CMR imaging
(pre discharge).
Secondary cardiac magnetic resonance imaging outcomes
The following outcomes were compared in the treatment arms at both CMR scans, except for those
underlined [at acute CMR scan only (pre discharge)] or in italic (at follow-up scan only):
l IS (% LVM) at 9 months
l number of discrete infarcts on CMR scan
l new MI (CMR imaging detected) at 9 months compared with acute CMR imaging
l LV volumes, LVEF and right ventricular (RV) ejection fraction
l IMH and MVO (% LVM)
l AAR (% LVM)
l baseline and final MSI
l proportion of patients with ischaemia and global ischaemic burden (% LV)
l visual presence of RV infarction, LV thrombus.
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Clinical outcomes
The following clinical end points were recorded (time points in brackets) and definitions are detailed in
Appendix 2:
l contrast-induced nephropathy (inpatient)
l vascular access injury requiring surgical repair (inpatient)
l all-cause mortality (all: inpatient, 6 week, 6 month, 12 month)
l MI (all)
l planned or repeat revascularisation (CABG or PCI) (all)
l heart failure admission (all)
l transient ischaemic attack/cerebrovascular event (all)
l major bleed (TIMI)73 (all).
FIGURE 11 The range of perfusion patterns possible. (a) Stress; (b) rest perfusion imaging, no perfusion defect (SDS=0
for segments in image); (c) stress and (d) rest perfusion imaging, with reversible transmural defect in anterolateral and
inferolateral segments (*SDS=2 for both segments); and (e) and (f) matched subendocardial perfusion defect in
infarcted basal inferior/inferolateral segments (*SDS=0 for segment). SDS, summed difference score.
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The primary clinical outcome for the main CvLPRIT was first combined MACE at 12 months (all-cause
mortality, MI, planned or repeat revascularisation, heart failure admission) and this was assessed for all
patients in the CMR imaging substudy. Secondary outcomes included individual clinical end points at
12 months and inpatient events (safety analysis).
Data handling
Cardiac MRI data were recorded in a lockable, validated74 Research Electronic Data Capture version 5.0
(REDCap) database (Vanderbilt University, Nashville, TN, USA). No clinical data were released to the CMR
imaging core laboratory until the database was complete, checked for errors and a locked copy provided
to the Clinical Trials and Evaluation Unit (CTEU). The CMR imaging database was locked on 13 June 2014
(see Appendix 3). Data entry into the REDCap database was automated, using data transposition from
automatically produced data files from CMR imaging analysis software. Complete data sets for 5% of
randomly selected patients were manually checked and 100% of these data were correct compared with
raw data files from CMR imaging software.
Patient and public involvement
As this grant application went through a fast-track application there was limited time to involve service
users. However, the study was presented, before initiation, to the patient and public involvement (PPI)
group of the NIHR Leicester Cardiovascular Biomedical Research Unit, and was welcomed. One patient
with a history of MI and previous PCI volunteered to join the Trial Steering Committee (TSC) and regularly
attended these meetings. The study progress was presented to the PPI group on two further occasions and
the chief investigator spoke to regional PPI meetings on active CMR imaging studies and heart disease,
including CvLPRIT-CMR imaging.
The plain English summary was forwarded to our patient representative, our PPI officer and the PPI
representatives. No specific concerns or suggestions for improvement were raised. Once the results have
been published the study will be presented at our local and regional PPI meetings to help disseminate
the findings.
Protocol changes
Original protocol (version 1.1) is dated 30 September 2010 and the final version of the protocol is
available online.75
Protocol (version 2) dated 30 March 2011
Summary of changes
l On page 15, section 12.1, Inclusion criteria: we have clarified that patients with LBBB with
angiographic confirmation of the occlusion of the IRA can also be included as guidelines also
recommend primary PCI for patients with clinical evidence of MI and LBBB.
l On page 15, section 12.1: Guidance for classification of multivessel coronary disease. We have
simplified the classification as follows:
For this study MVD is considered to be the IRA plus at least one non-infarct related epicardial artery
(N-IRA) with at least one lesion deemed angiographically ‘significant’ (i.e. > 70% diameter stenosis
observed in at least one plane). The non-IRA should be a major (> 2mm) epicardial coronary artery
or branch (> 2mm) and be suitable for stent implantation.
Gershlick et al.75
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In the original protocol, patients with > 50% coronary artery stenosis could be entered, which the TSC felt
was not sufficiently narrow. In addition, the original protocol states that non-IRA vessels ≥ 2mm could be
treated, whereas the TSC wanted to ensure that vessels are > 2mm (not equal to 2mm as was stated in
the original protocol).
l On page 15, section 12.2, Exclusion criteria: we have reworded the current exclusion criterion number
8 from ‘STEMI thought to be due to occlusion of a coronary artery bypass graft’ to ‘Patients with
previous coronary artery bypass graft (CABG)’. TSC members agreed that these patients often need a
different revascularisation strategy from patients without prior CABG and, therefore, would be best
excluded from the study. For clarity we have also removed the text ‘Clear indication for or’ from
exclusion criterion 3.
l We have also clarified that patients with stent thrombosis be excluded from the study by adding the
exclusion criterion: ‘Suspected or confirmed thrombosis of a previously stented artery’.
l On page 17, Table 3, Summary of baseline, randomisation and follow-up procedures: we have included
CK blood test. CK is a routine blood test to assess myocardial damage in STEMI patients. Also,
post-procedural ECG (at 90 minutes after the procedure) is also usual clinical practice in STEMI patients.
Therefore, the TSC members decided to collect this useful data.
l On page 18, section 14, In-hospital management: we have clarified current in-hospital management
regarding use of stents. The TSC members recommended using DESs, as the stents of choice as
there is growing evidence and acceptance that these are the ‘standard of care’ in comparison to
bare-metal stents.
l On page 19, section 14, In-hospital management: we clarified the in-hospital management of patients
with renal impairment. Specifically, we recommend that patients found to have significant renal
impairment after randomisation should be treated according to the best clinical practice.
l On page 20, section 15.1, Follow-up: we have changed the ischaemic burden threshold from 15% to
20% to disclose MPS results to the clinicians in charge of the patients. The TSC members agreed that
there was some evidence of improved prognosis when patients were managed more aggressively for
ischaemic burden > 20% by MPS (although this evidence is generated from observational studies),
but little or no evidence of improved outcomes with more aggressive treatment when the ischaemic
threshold is < 20%.
Protocol (version 2.1) dated 15 December 2011
Summary of changes
l The research team have identified that assent for some patients may not be appropriate if they already
know they will not be eligible for randomised part of the trial and it would therefore be more
appropriate to gain written consent to participate in the registry after the procedure. Therefore, the
inclusion criterion for the registry patient was changed in the protocol from ‘provision verbal assent
followed by written informed consent’ to ‘provision of written informed consent’.
Protocol (version 2.2) dated 1 February 2013
Summary of changes
l In the last CvLPRIT TSC meeting the members agreed that CvLPRIT should recruit 300 patients to the
randomised part of the trial. This allows at least 200 patients to be included in the CMR scans. We had
anticipated that the CMR scans would be 80% of all patients randomised, so our initial aim was for
250 patients to provide the 200 CMR scans. The current CMR scan rate is 75%, but has been
as low as 70%. Therefore, based on a CMR scans range of 70–75%, we will require between
268 and 285 patients in the main study to provide the 200 CMR scans. The recruitment of 300 is
based on the worst-case scenario of 70%.
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l Three more investigator sites (Kettering, Derby and Bournemouth) have been added to the original
four sites and a total of seven sites are currently recruiting.
l There is also a clarification added to the trial MI definition in page 32 of the protocol.
Statistical methods
Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS version 20; IBM
Corporation, Armonk, NY, USA). Primary and secondary outcomes were analysed according to an
intention-to-treat basis. As the primary CMR imaging outcome (IS) was expected to be right skewed, it was
pre-specified to be log-transformed for all analyses in order to obtain approximately normally distributed
data. Linear regression was undertaken to assess baseline characteristics associated with IS. The results for
IS were adjusted for univariate predictors of IS (p< 0.1) and other covariates known to affect IS (DM and
sex) using generalised linear models. As AAR was only available in 74% of patients, adjustments were
made with and without this included in the model. To test whether or not the results were affected by the
distribution of the variables, each analysis was rerun as a generalised estimating equation (GEE), making
use of the robust standard error. The GEEs produced very similar results to our primary analyses and,
hence, only the original univariate results are reported here.
For other outcome variables, normality was assessed using Q–Q plots, Kolmogorov–Smirnov and
Shapiro–Wilk tests. Normally distributed continuous variables were expressed as mean± standard deviation
(SD), and non-normally distributed data as medians (25–75th quartiles). Comparison of normally
distributed continuous outcomes in the study arms was performed with independent t-testing.
Variables that could not be normalised despite progressive transformation attempts were analysed using
non-parametric testing (Mann–Whitney U-tests) and have ‘§’ after the p-value. Categorical variables
were summarised with the number and proportion of participants in each category and compared using
chi-squared testing or Fisher’s exact test as appropriate.
Interobserver and intraobserver variability
Interobserver and intraobserver agreement were assessed on 10 randomly selected acute CMR scans using
two-way mixed-effect intraclass correlation coefficients (ICCs) for absolute agreement76 and Bland–Altman
analysis.77 The ICC agreement was defined as excellent (ICC ≥ 0.75), good (ICC 0.60–0.74), fair (ICC
0.40–0.59) or poor (ICC < 0.40).78 Intraobserver agreement was assessed using requantification by a single
observer (JNK) after a 2-month interval and interobserver agreement was assessed by comparing
observations of two independent observers (JNK and SN).
Assessment of clinical outcomes
Inpatient safety outcomes were compared in the two treatment arms using chi-squared testing. Results
were presented as odds ratios (ORs) with 95% CIs. The 12-month clinical outcomes were compared in the
two treatment arms in CMR imaging substudy patients. These analyses were performed for time to first
event with survival analysis using the log-rank test (Cox regression) with right censoring. Results were
presented as HRs with their 95% CIs. The Schoenfeld residuals output test was used to confirm the validity
of the proportional hazards model. Kaplan–Meier survival curves were produced for the subgroups.
Sample size
There are no published CMR data comparing the revascularisation strategies. There are however numerous
data on unselected patients undergoing the PPCI and CMR imaging IS,37,40,79 which are similar to that seen
in our centre. A total of 100 patients in each arm had 81% power to detect a 4% absolute difference in
IS, assuming a IS ≈20% of LVM, a SD of 10%, α= 0.05 and two-tailed given that either strategy may be
associated with a larger IS. A new IS of 4% of LVM is associated with adverse prognosis in CAD patients
with revascularisation-related injury.27
METHODS
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Study organisation
Trial management and governance
The CvLPRIT was sponsored by University Hospitals of Leicester NHS Trust. The University of Leicester was
the co-ordinating centre responsible for CMR imaging substudy management, including production of
final protocols, case record forms, standard operating procedures, data handling, quality assurance and
statistical reporting. Regular progress reports were provided to relevant parties. Close liaison with the Royal
Brompton CTEU, that co-ordinated the main CvLPRIT, occurred throughout the study.
The main trial and CMR imaging substudy were overseen by a TSC, with the chairperson and two members
being independent of the investigators. There was an independent Data and Safety Monitoring Board
(DSMB) that constituted reviewed clinical outcomes during the study. An interim data review performed by
the DSMB in October 2012 (16 months after recruitment started, at which point 147 patients had been
recruited into the CMR imaging substudy and 36 had undergone 9-month follow-up CMR imaging) was
satisfied with progress to date and for the trial to continue (see Appendix 4).
This CMR imaging substudy was funded by the MRC through the EME programmed (project number
09/150/28) and managed by the NIHR on behalf of the MRC–NIHR partnership. The main trial was funded
by the BHF.
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Chapter 4 Results
The main Complete versus Lesion-only PRimary percutaneous
coronary Intervention Trial
The main trial screened 850 patients presenting with STEMI, of whom 296 were randomised. The main
results of the trial were presented at the ESC Annual congress in Barcelona, Spain, in August 2014 and
were published in the Journal of the American College of Cardiology.80 Patient groups were well matched
for baseline clinical characteristics. The primary end point (MACEs) occurred in 10.0% of the CR group,
compared with 21.2% in the IRA-only revascularisation group (HR 0.45, 95% CI 0.24 to 0.84; p= 0.009).
A trend towards benefit was seen early following CR (p= 0.055 at 30 days). Although there was no
significant reduction in death or MI, a non-significant reduction in all primary end-point components was
seen. There was no reduction in ischaemic burden on MPS or in the safety end points of major bleeding,
contrast-induced nephropathy or stroke between the groups.80
Complete versus Lesion-only PRimary percutaneous coronary
Intervention Trial cardiac magnetic resonance substudy
The proportion of patients randomised and completing study aspects are shown in Figure 12. A total of
91% (n= 269) of the 296 randomised patients consented to ongoing participation in CvLPRIT, of whom
76% (n= 205) entered the CMR imaging substudy. LGE images from one patient were unanalysable and
one patient did not complete the acute CMR scan, resulting in 203 acute CMR scans analysable for the
primary CMR imaging outcome. The recruitment target of 200 was exceeded, as four patients were
recruited on the final day.
The reasons for non-participation in the CMR imaging substudy and drop-out from the second CMR scan
are shown in Table 7. A total of 81% (164/203) of eligible patients had follow-up CMR scans, as per
Figure 12. Those who did not have a second CMR scan had similar baseline characteristics to those who
completed both scans.
The CMR imaging substudy completed recruitment 1 month before the main trial and 13 patients
randomised were not approached to participate in the CMR imaging substudy.
Recruitment in the main trial and substudy at each centre is shown in Table 8.
Baseline characteristics of the cardiac magnetic resonance substudy cohort
The CMR imaging substudy cohort closely represented the overall CvLPRIT group, with similar baseline
characteristics, comorbidities and important prognostic predictors including symptom to the PPCI time
[time to revascularisation (TTR)], infarct location and Killip class (Table 9).
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Did not go into
CMR substudy 
(n = 43)
Assented and randomised 
(n = 296)
CR 
(n = 150)
• Complete, n = 141
• IRA only, n = 6
• IRA only + CABG, n = 3
IRA only 
(n = 146)
Consented 
(n = 141)
Declined consent
 (n = 9)
CMR substudy 
(n = 98) (70%)
Analysable baseline CMRs 
(n = 98)
9-month CMR
(n = 84)
Patients excluded (n = 2) 
• Incomplete exam, n = 1
• Non-diagnostic LGE, n = 1
Declined consent 
(n = 18)
• IRA only, n = 139
• Complete, n = 6
• IRA + CABG, n = 1
CMR substudy 
(n = 107) (84%)
Analysable baseline CMRs 
(n = 105)
Did not go into
CMR substudy 
(n = 21)
Did not have
9-month CMR 
(n = 14)
Did not have
9-month CMR 
(n = 25)
9-month CMR
(n = 80)
Consented 
(n = 128)
FIGURE 12 Complete versus Lesion-only PRimary percutaneous coronary Intervention Trial cardiac magnetic
resonance substudy recruitment: CONSORT (Consolidated Standards of Reporting Trials) diagram illustrating
recruitment into main CvLPRIT and CMR imaging substudy. Reproduced under Creative Commons CC BY license
from McCann GP, Khan JN, Greenwood JP, Sheraz N, Dalby M, Curzen N, et al. Complete versus lesion-only primary
PCI: the randomized cardiovascular MR CuLPRIT substudy. J Am Coll Cardiol 2015;66:2713–24.
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TABLE 7 Reasons for non-participation in the CMR imaging substudy and follow-up CMR scans
Reason Number of participants
Reasons for patients consenting to enter CvLPRIT but not entering the CMR imaging substudy
Patient declined consent to enter the CMR imaging substudy 9
Claustrophobia 14
Renal failure 2
CMR imaging contraindicated 4
Too unwell for CMR imaging/death 7
After CMR imaging substudy 13
No CMR imaging available at centre at time of consent into CvLPRIT 10
Other 2
Repatriated to district general hospital 3
Total 64
Reasons for patients in the CMR imaging substudy but not returning for follow-up CMR scan
Patient withdrawn from CvLPRIT 3
Patient declined follow-up CMR scan 26
Death 3
Implantable cardioverter defibrillator 1
Other severe illness 1
Follow-up CMR scan due after end of CMR imaging substudy period 3
Claustrophobia 2
Total 39
TABLE 8 Recruitment at the study centres
Centre
Number of patients randomised
(% of total)
Number of patients in CMR
imaging substudy (%)
Glenfield 99 (33.4) 78 (78.8)
Southampton 35 (11.8) 26 (77.1)a
Leeds 57 (19.3) 32 (56.1)
Harefield 38 (12.8) 26 (68.4)
Kettering 32 (10.8) 26 (81.3)
Derby 20 (6.8) 12 (60.0)
Bournemouth 15 (5.1) 3 (26.7)b
Total 296 203 diagnostic
a One patient excluded from CMR imaging substudy because of unanalysable LGE images.
b One patient excluded from CMR imaging substudy as unable the acute CMR scan was unable to be completed.
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Anthropometrics and demographics
Baseline characteristics and comorbidities were closely matched in the IRA and CR treatment arms of the
CMR imaging substudy cohort (Table 10). There were slightly more males in the CR arm but the difference
was not significant (CR 88.8% vs. IRA-only 79.0%; p= 0.06). The proportion of anterior infarcts in each
arm was closely matched.
Antiplatelet and discharge medication
Discharge medications were similar in the treatment arms. All patients received DAPT. Two-thirds of
patients in each arm received newer DAPT agents, prasugrel or ticagrelor (Table 11).
Angiographic markers
Radial artery access was the preferred technique in both treatment arms. Coronary disease complexity,
severity and IRA at baseline angiography were similar in the groups. There was a greater proportion of CR
patients with well-collateralised IRA territory, defined as Rentrop grade 2 or 3 (Table 12).
Percutaneous coronary intervention details
In the main trial, 42 out of the 139 CR patients who received the allocated treatment had a staged PCI to
the non-IRA and, in the CMR imaging substudy, 30 non-IRA PCI patients were staged. Total screening
time, contrast dose, procedure length and number of implanted stents were greater in CR patients. The
majority of patients in both arms received DESs, although this proportion was slightly higher in CR patients
(see Table 13). Symptom to balloon times (TTR), peri-PCI adjunct usage and post-PPCI CK were similar in
both arms (Table 13). No reflow in the IRA patients was more common in the CR group.
TABLE 9 Baseline characteristics of the main CvLPRIT and CMR imaging substudy cohort
Variable
Overall CvLPRIT
group (n= 296)
CMR imaging substudy
cohort (n= 203) p-value
95% CI of
difference
Age (years), mean (SD) 64.9± 11.6 63.6± 11.0 0.21 –0.7 to 3.3
Male sex, n/N (%) 240/296 (81.1) 172/205 (83.9) 0.42 N/Aa
BME n/N (%) 33/293 (11.3) 22/200 (11.0) 0.93 N/Aa
BMI (kg/m2), median (IQR) 27.3 (24.4–30.2) 27.5 (24.7–30.1) 0.62 –0.02 to 0.01b
SBP (mmHg), mean (SD) 137.6 (27.1) 137.5 (27.7) 0.96 –4.8 to 5.1
Hypertension, n/N (%) 105/287 (36.6) 73/203 (36.0) 0.89 N/Aa
Hypercholesterolaemia, n/N (%) 75/287 (26.1) 56/203 (27.6) 0.72 N/Aa
DM, n/N (%) 39/287 (13.6) 28/203 (13.8) 0.95 N/Aa
Current smoker, n/N (%) 87/285 (30.5) 66/204 (32.4) 0.67 N/Aa
Previous MI, n/N (%) 12/287 (4.2) 8/203 (3.9) 0.90 N/Aa
Previous PCI, n/N (%) 9/287 (3.1) 7/203 (3.4) 0.85 N/Aa
Symptom PCI time (TTR, minutes),
median (IQR)
184 (131–304) 177 (130–292) 0.49 –0.03 to 0.06b
Peak CK (IU/l), mean (IQR) 1010 (423.3–1740) 997 (429.8–1740) 0.98 –0.09 to 0.08b
Anterior infarct, n/N (%) 106/296 (35.8) 72/203 (35.5) 0.94 N/Aa
Killip class II or III on arrival, n/N (%) 24/286 (8.4) 16/203 (7.9) 0.84 N/Aa
BME, black or minority ethnicity; BMI, body mass index; IQR, interquartile range; N/A, not applicable; SBP systolic
blood pressure.
a Categorical data assessed using chi-squared analysis.
b Log10-transformed variable.
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TABLE 10 Baseline characteristics of the IRA and CR CMR imaging substudy
Variable
Treatment arm
p-value 95% CI of differenceIRA (n= 105) CR (n= 98)
Anthropometrics
Age (years), mean (SD) 64.1± 10.8 63.1± 11.3 0.53 –0.9 to 6.8
Male sex, n/N (%) 83/105 (79.0) 87/98 (88.8) 0.06 N/Aa
BME, n/N (%) 9/103 (8.7) 13/97 (13.4) 0.29 N/Aa
BMI (kg/m2), median (IQR) 27.5 (24.7–30.6) 27.5 (24.6–29.7) 0.36 0.02 to 0.01b
SBP (mmHg), mean (SD) 140.0± 28.0 134.7± 27.3 0.18 –8.4 to 11.3
Anterior infarct, n/N (%) 37/105 (37.2) 35/98 (35.7) 0.94 N/Aa
Killip class II or III on arrival, n/N (%) 10/105 (9.5) 6/98 (6.1) 0.37 N/Aa
Biochemical
eGFR (ml/minute/1.73m2), mean (SD) 93.49 (30.7) 98.2 (34.3) 0.36 –15.8 to 7.4
Peak CK (IU/l), median (IQR) 1057 (614–1834) 1025 (628–1660) 0.37 –0.16 to 0.14b
Past medical history
Hypertension, n/N (%) 37/105 (35.2) 36/98 (36.7) 0.82 N/Aa
Hypercholesterolaemia, n/N (%) 28/105 (26.7) 28/98 (28.6) 0.76 N/Aa
DM, n/N (%) 13/105 (12.4) 15/98 (15.3) 0.55 N/Aa
Current smoker, n/N (%) 28/105 (28.0) 36/98 (36.7) 0.12 N/Aa
Previous MI, n/N (%) 4/105 (3.8) 4/98 (4.1) 0.92 N/Aa
Previous PCI, n/N (%) 3/105 (2.9) 4/98 (4.1) 0.63 N/Aa
BMI, body mass index; IQR, interquartile range; N/A, not applicable; SBP, systolic blood pressure.
a Categorical data assessed using chi-squared analysis.
b Log10-transformed variable.
TABLE 11 Antiplatelet and discharge medications
Discharge medications
Treatment arm
p-valueIRA (n= 105) CR (n= 98)
Aspirin, n/N (%) 105/105 (100) 97/98 (99.0) 0.30
Dual antiplatelet agent, n/N (%) 105/105 (100) 98/98 (100) 1.00
Clopidogrel 36/105 (34.3) 34/98 (34.7) 0.95
Prasugrel 53/104 (51.0) 49/98 (50.0) 0.89
Ticagrelor 16/105 (14.3) 15/98 (15.3) 0.91
Warfarin, n/N (%) 0/105 (0.0) 2/98 (2.0) 0.14
Beta-blocker, n/N (%) 97/105 (92.4) 93/98 (94.9) 0.46
ACE or ARB2 inhibitor, n/N (%) 101/105 (96.2) 95/98 (96.9) 0.77
Lipid-lowering agent, n/N (%) 104/105 (99.1) 98/98 (100) 0.33
Loop diuretic, n/N (%) 13/105 (12.4) 9/98 (9.2) 0.46
Aldosterone inhibitor, n/N (%) 5/105 (4.8) 5/98 (5.1) 0.91
Oral diabetic drug, n/N (%) 8/105 (7.6) 8/98 (8.2) 0.89
Insulin, n/N (%) 7/105 (6.7) 4/98 (4.1) 0.42
ARB2, angiotensin 2 receptor blocker.
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TABLE 12 Baseline angiographic markers
Variable
Treatment arm
p-value
95% CI of
differenceIRA (n= 105) CR (n= 98)
Radial access, n/N (%) 82/105 (78.1) 81/97 (83.5) 0.33 N/Aa
Visible thrombus, n/N (%) 71/105 (67.6) 60/97 (61.9) 0.39 N/Aa
Vessels > 75% stenosis (n), mean (SD) 1.5 (0.6) 1.5 (0.6) 0.39 b
Total lesions > 75% stenosis (n), mean (SD) 1.6 (0.7) 1.6 (0.7) 0.58 b
Non-IRA lesions > 75% stenosis (n), mean (SD) 0.6 (0.7) 0.6 (0.7) 0.58 b
Vessels > 70% QCA stenosis (n), mean (SD) 1.8 (0.6) 1.7 (0.6) 0.82 b
Total lesions > 70% QCA stenosis (n), mean (SD) 1.9 (0.8) 1.9 (0.8) 0.95 b
Non-IRA lesions > 70% QCA stenosis (n), mean (SD) 0.9 (0.8) 0.9 (0.8) 0.86 b
Left anterior descending IRA, n/N (%) 38/105 (36.2) 34/98 (34.7) 0.82 N/Aa
Left circumflex artery IRA, n/N (%) 18/105 (17.1) 20/98 (20.4) 0.55 N/Aa
Right coronary artery IRA, n/N (%) 48/105 (45.7) 44/98 (44.9) 0.91 N/Aa
Rentrop grade, median (IQR) 0 (0–1) 0 (0–1) 0.14 –0.11 to 0.02c
Rentrop grade 2 or 3 pre PCI, n/N (%) 3/105 (2.9) 10/98 (10.2) 0.033 N/Aa
TIMI grade pre PCI, median (IQR) 0 (0–1) 0 (0–1) 0.56 –0.15 to 0.08c
TIMI pre-PCI grades 0–2, n/N (%) 97/105 (92.4) 89/98 (90.8) 0.69 N/Aa
SYNTAX score (total), median (IQR) 18 (14–22) 17.3 (13–23.5) 0.81 –2.3 to 1.8
SYNTAX score (IRA), median (IQR) 9 (6–14.5) 8 (6–11.5) 0.75 –1.3 to 1.8
SYNTAX score (non-IRAs), median (IQR) 7 (3–11) 7 (4–10) 0.51 –0.12 to 0.06
IQR, interquartile range; N/A, not applicable.
a Categorical data assessed using chi-squared analysis.
b Non-transformable non-normally distributed variable assessed using Mann–Whitney U-testing.
c Log10-transformed variable.
Bold indicates statistically significant p-value.
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Acute cardiac magnetic resonance
Cardiac magnetic resonance image quality
Acute CMR imaging was undertaken at approximately 3 days post PPCI in both treatment arms.
One hundred per cent of cine and LGE images in the final 203 CMR imaging substudy subjects were of
very good quality (Table 14). Fifty-two patients’ (26%) short-tau inversion recovery (STIR) data sets were
non-diagnostic [no artefact but no oedema discernible (n= 33); STIR not performed because of arrhythmia
or suboptimal breath-holding (n= 14); and severe artefact (n= 5)]. Image quality was similar in both
treatment arms.
Observer variability
Intra- and interobserver variability were excellent for CMR imaging volumetric and tissue characterisation
(AAR and IS). Results are displayed in Table 15.
TABLE 13 Primary PCI data
Variable
Treatment arm
p-value
95% CI of
differenceIRA (n= 105) CR (n= 98)
Glycoprotein inhibitor use, n/N (%) 36/104 (34.6) 34/97 (35.1) 0.95 N/Aa
Bivalirudin use, n/N (%) 43/94 (45.7) 52/92 (56.5) 0.14 N/Aa
Thrombectomy catheter use, n/N (%) 79/105 (75.2) 67/97 (69.1) 0.33 N/Aa
Contrast dose (ml), median (IQR) 190 (150–230) 300 (220–400) < 0.001 –0.26 to –0.16b
Screening time (minutes), median (IQR) 9 (7–13) 17 (12–23) < 0.001 –0.35 to –0.22b
Procedure length (minutes), median (IQR) 42 (30–55) 66 (43–84) < 0.001 –0.25 to –0.13b
Symptom PCI time (TTR, minutes), median (IQR) 171 (127–268) 192 (131–302) 0.20 –0.13 to –0.12
TIMI grade post PCI, median (IQR) 3 (3–3) 3 (3–3) 0.31 –0.5 to –0.2
TIMI post PCI, grade 3, n/N (%) 100/105 (95.2) 89/98 (90.8) 0.21 N/A
Successful IRA PCI, n/N (%) 101/105 (96.2) 90/98 (91.8) 0.19 N/A
IRA no reflow, n/N (%) 2/105 (1.9) 8/98 (8.2) 0.039 N/A
IRA PCI complication, n/N (%) 14/105 (13.3) 8/98 (8.2) 0.24 N/A
DES use, n/N (%) 96/105 (91.4) 97/98 (99) 0.013 N/A
Total number of stents (n), median (IQR) 1 (1–2) 3 (2–4) < 0.001 c
Peak CK (IU/l), median (IQR) 1057 (614–1834) 1025 (628–1660) 0.37 –0.17 to 0.06b
Time at peak CK (hours), median (IQR) 12 (12–12) 12 (12–12) 0.98 –0.05 to 0.52b
IQR, interquartile range; N/A, not applicable.
a Categorical data assessed using chi-squared analysis.
b Log10-transformed variable.
c Non-transformable non-normally distributed variable assessed using Mann–Whitney U-testing.
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Cardiac magnetic resonance outcomes
Predictors of infarct size
Univariate predictors of IS are shown in Table 16. The primary outcome was adjusted for variables with
p< 0.1 (age, anterior MI, TIMI grade prior to the PPCI, TTR, male sex, SYNTAX score plus DM and sex).
Given that anterior infarct location (ECG based) is closely related to left anterior descending artery IRA,
only anterior infarct location was used.
Myocardial and microvascular injury and salvage
There was no difference in the primary CMR imaging outcome of median IS {IRA 13.5% [interquartile
range (IQR) 6.2–21.9%] vs. CR 12.6% (IQR 7.2–22.6%); 95% CI –4.09% to 31.17%; p= 0.57}.
Adjustment for important covariates including AAR (p= 0.347) or without AAR included (p= 0.501) did
not significantly change the results. There was also no difference in IRA IS or number of transmurally
infarcted segments in the treatment arms (Table 17). LGE was absent in 13 patients, of whom eight were
confirmed aborted infarcts (oedema present but no LGE), with a trend towards fewer aborted infarcts
(p= 0.06) with CR. There was a significantly higher prevalence of multiple infarcts and multiple acute
infarcts with CR.
TABLE 14 Acute CMR image quality
Variable
Treatment arm
p-value 95% CI of differenceIRA (n= 105) CR (n= 98)
Time to acute CMR scan (days), median (IQR) 2.8 (1.8–3.4) 3.0 (2.0–4.3) 0.13 –0.13 to 0.02
Cine imaging quality score, mean (SD) 2.4 (0.8) 2.5± 0.7 0.31 –0.30 to 0.10
Oedema imaging diagnostic, n/N (%) 76/105 (72.4) 75/98 (76.5) 0.50 N/Aa
Oedema image quality score, mean (SD) 1.3 (0.9) 1.4± 0.9 0.53 –0.34 to 0.17
LGE image quality score, mean (SD) 1.9 (0.7) 2.0± 0.6 0.13 –0.33 to 0.04
IQR, interquartile range; N/A, not applicable.
a Categorical data assessed using chi-squared analysis.
TABLE 15 Intra- and interobserver variability of CMR imaging measurements
CMR imaging variable
Intraobserver agreement Interobserver agreement
ICC Mean bias ± 95%, LoA ICC Mean bias ± 95%, LoA
Volumetric analysis
LVM index 0.986 –0.3 +6.3, –6.8 0.995 + 0.5 +4.4, –3.5
LV end-diastolic volume index 0.996 +1.2 +6.4, –4.0 0.995 + 1.3 + 7.9, –5.3
LVESV index 0.988 –0.9 +4.6, –6.4 0.996 + 0.8 + 6.4, –4.8
LVEF (%) 0.976 +1.0 +3.8, –1.8 0.996 –0.1 + 1.4, –1.6
Tissue characterisation
IS 0.988 +0.2 +1.5, –1.1 0.990 –0.5 + 1.7, –2.7
AAR 0.948 +2.8 +7.3, –1.7 0.908 +3.4 + 9.1, –2.4
LoA, limits of agreement.
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TABLE 16 Univariate predictors of IS
Variable Baseline IS, r (r2) p-value
Anthropometrics
Age 0.15 (0.22) 0.04
Male sex –0.02 (0.00) 0.98
SBP –0.02 (0.00) 0.79
Anterior infarct 0.27 (0.07) < 0.001
Past medical history
Treated hypertension –0.06 (< 0.01) 0.42
Treated hypercholesterolaemia –0.09 (< 0.01) 0.22
DM 0.06 (< 0.01) 0.41
Coronary angiography
Killip class II or III on arrival 0.11 (0.13) 0.12
Visible thrombus < 0.01 (< 0.01) 0.90
Symptom to PCI time (TTR, minute) 0.11 (0.01) 0.14
LAD IRA 0.21 (0.05) 0.003
Rentrop grade 0.05 (< 0.01) 0.71
Rentrop grade 2 or 3 pre PCI 0.04 (< 0.01) 0.64
TIMI grade pre PCI –0.27 (0.07) 0.06
SYNTAX score (total) 0.31 (0.10) < 0.001
Number of affected vessels > 75% (CRF) 0.10 (0.01) 0.15
Number of total lesions > 75% (CRF) 0.06 (< 0.01) 0.39
Number of non-IRA lesions > 75% (CRF) 0.06 (< 0.01) 0.39
Number of affected vessels > 75% (QCA) 0.16 (0.02) 0.03
Number of total lesions > 75% (QCA) 0.12 (0.02) 0.09
Number of non-IRA lesions > 75% (QCA) 0.12 (0.02) 0.09
Baseline CMR imaging parameters (CMR1)
AAR (% LVM) 0.54 (0.29) < 0.001
CRF, case report form; LAD, left anterior descending artery; SBP, systolic blood pressure.
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TABLE 17 Tissue characterisation data at acute CMR scan
Tissue characterisation variable
Treatment arm
p-value
95% CI of
differenceIRA (n= 105) CR (n= 98)
Infarct present on LGE, n/N (%) 95/105 (90.5) 95/98 (96.9) 0.06 N/Aa
MVO present, n/N (%) 54/105 (51.4) 57/98 (58.2) 0.34 N/Aa
IMH present in diagnostic STIR sets, n/N (%) 17/77 (22.1) 22/75 (29.3) 0.31 N/Aa
Total IS (% LVM)b
Median (IQR) 13.5 (6.2–21.9) 12.6 (7.2–22.6) 0.57 –4.09 to 31.17
Mean (SD) 15.9 (13.2) 16.3 (13.0)
Patients with > 1 infarct, n/N (%) 11/105 (10.5) 22/98 (22.4) 0.02 N/Aa
Patients > 1 acute infarct, n/N (%) 5/105 (4.8) 17/98 (17.1) 0.004 N/Aa
IRA IS (main acute infarct, % LVM)
Median (IQR) 12.2 (6.2–21.2) 12.1 (7.0–21.4) 0.68 –0.16 to 0.10c
Mean (SD)b 15.3 (13.2) 15.2 (12.1)
Non-IRA IS (acute non-IRA infarcts, % LVM)
Median (IQR) 2.1 (0.81–4.5) 2.5 (0.54–4.5) 0.004 3940 to 21229c
Mean (SD)a 2.5 (1.9) 3.2 (3.3)
Acute non-IRA IS > 4% LVM, n/N (%) 2/105 (1.9) 6/98 (6.1) 0.12 N/Aa
AAR (% LVM), mean (SD) 36.0 (12.9) 32.2 (11.8) 0.06 –0.12 to 7.9
MVO (% LVM),d mean (SD) 0.08 (0.00–1.05) 0.19 (0.00–2.00) 0.63 0.58 to 0.67
IMH (% LVM), median (IQR) 0.00 (0.0–0.20) 0.00 (0.0–0.34) 0.96 0.50 to 0.54
Acute MSI (%), median (IQR) 60.5 (40.6–81.9) 58.5 (32.8–74.9) 0.14 –2.2 to 16.3
Final MSI (%), median (IQR) 79.4 (71.6–93.3) 82.1 (63.0–90.3) 0.20 –3.1 to 15.2
Patients with > 1 infarct, n/N (%) 11/105 (10.5) 22/98 (22.4) 0.02 N/Aa
Patients > 1 acute infarct, n/N (%) 5/105 (4.8) 17/98 (17.3) 0.004 N/Aa
Number of infarcts per patient, mean (SD) 1.02 (0.4) 1.22 (0.5) < 0.001 –0.0752 to –0.0753c
Number of acute infarcts per patient,
mean (SD)
1.05 (0.2) 1.19 (0.4) < 0.001 –0.0687 to –0.0693c
RV infarction, n/N (%) 4/105 (3.8) 7/98 (7.1) 0.29 N/A
LV thrombus, n/N (%) 3/105 (2.9) 2/98 (2.0) 0.71 N/A
N/A, not applicable.
a Categorical data assessed using chi-squared analysis.
b Primary end point.
c Log10-transformed variable.
d Non-transformable non-normally distributed variable assessed using Mann–Whitney U-testing.
Bold text indicates significant p-values.
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There was a trend towards a higher prevalence of acute non-IRA infarcts > 4% LVM with CR. Acute
non-IRA infarcts correlated with non-IRA PCI territories in 15 out of 17 CR patients. There was a
non-significant trend towards smaller AAR with CR, but no difference in the MSI. Microvascular and RV
injury, and LV thrombus were similarly prevalent in both arms.
Ventricular volumes and function
Left ventricular volumes, mass and systolic function (LVEF), were similar in the treatment arms (Table 18).
LV function was similarly mildly impaired on LVEF.
Follow-up cardiac magnetic resonance imaging
Cardiac magnetic resonance image quality
Follow-up CMR imaging was undertaken approximately 9.4 months post PPCI in both treatment arms and
all scans were analysable. Image quality for all sequences was very good (Table 19). Three patients were
unable to undertake adenosine stress perfusion because of airways disease (two in the IRA-only group and
one in the CR group). Perfusion imaging was unanalysable in two patients because of severe dark-rim
artefact (one in the IRA-only group and one in the CR group).
TABLE 18 Ventricular volumes and function data at acute CMR scan
Volumetric variable
Treatment arm
p-value 95% CI of differenceIRA (n= 105) CR (n= 98)
Number of dysfunctional segments,
median (IQR)
5.0 (3–7) 5.0 (3–7) 0.64 –0.64 to 1.1
Wall motion score, median (IQR) 23.0 (19–26) 22.0 (19–26) 0.71 –1.2 to 1.8
LVMI (g/m2), median (IQR) 52.2 (44.7–59.2) 52.3 (46.8–62.0) 0.33 –0.39 to 0.13a
LVEDVI (ml/m2), median (IQR) 90.7 (80.4–102.0) 89.7 (80.7–101.8) 0.64 –0.19 to 0.03a
LVESVI (ml/m2), median (IQR) 49.8 (39.7–62.1) 47.0 (38.0–58.4) 0.56 –0.03 to 0.05a
LVEF (%), mean (SD) 45.1 (9.5) 45.9 (9.9) 0.60 –3.4 to 2.0
LVEDVI, LV end-diastolic volume index; LVESVI, LV end-systolic volume index.
a Log10-transformed variable.
TABLE 19 Follow-up CMR image quality
Variable
Treatment arm
p-value 95% CI of differenceIRA (n= 80) CR (n= 84)
Time to follow-up CMR scan (months),
median (IQR)
9.3 (8.9–9.9) 9.4 (9.0–10) 0.20 –0.51 to 0.11
Cine imaging quality score, mean (SD) 2.8 (0.6) 2.7 (0.6) 0.58 –0.12 to 0.22
LGE image quality score, mean (SD) 2.2 (0.7) 2.3 (0.7) 0.74 –0.25 to 0.18
Stress perfusion diagnostic, n/N (%) 76/79 (96.2) 82/84 (97.6) 0.60 N/Aa
Stress perfusion quality score, mean (SD) 2.4 (0.7) 2.4 (0.8) 0.70 –0.29 to 0.19
Rest perfusion diagnostic, n/N (%) 76/79 (96.2) 82/84 (97.6) 0.60 N/Aa
Rest perfusion quality score, mean (SD) 2.5 (0.6) 2.5 (0.7) 0.82 –0.23 to 0.18
N/A, not applicable.
a Categorical data assessed using chi-squared analysis.
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Cardiac magnetic resonance imaging outcomes
Ventricular volumes and function
Left ventricular volumes, mass and systolic function (LVEF) were similar in the groups at the follow-up CMR
scan (Table 20). LV function was mildly impaired in both treatment groups.
Myocardial injury
As per acute CMR imaging, a greater proportion of CR patients had LGE and multiple infarcts. Total IS was
significantly different in the treatment arms (Table 21). There was a greater prevalence of residual RV
infarction in the CR group.
TABLE 21 Tissue characterisation data at follow-up CMR scan
Tissue characterisation
variable
Treatment arm
p-value 95% CI of differenceIRA (n= 80) CR (n= 84)
Infarct present on LGE, n/N (%) 71/80 (88.8) 82/84 (97.6) 0.023 N/Aa
IS (% LVM), median (IQR) 7.6 (3.2–15.1) 7.3 (3.0–14.4) 0.41 –0.08 to 0.20b
Transmural LGE area extent
> 50% (segments),
median (IQR)
0 (0–1) 0 (0–1) 0.96 c
Patients with >1 infarct, n/N (%) 9/80 (11.2) 20/84 (23.8) 0.035 N/Aa
Non-IRA IS (% LVM) in
patients with > 1 infarct,
median (IQR)
4.1 (2.3–8.1) 4.2 (1.9–6.1) 0.92 –0.48 to 0.54b
Number of infarcts per patient,
mean (SD)
1.03 (0.5) 1.24 (0.5) < 0.001 –0.780 to –0.773b
RV infarction, n/N (%) 0/80 (0.0) 5/84 (6.0) 0.027 N/Aa
LV thrombus, n/N (%) 1/80 (1.2) 1/84 (1.2) 0.97 N/Aa
a Categorical data assessed using chi-squared analysis.
b Log10-transformed variable.
c Non-transformable non-normally distributed variable assessed using Mann–Whitney U-testing.
Bold text indicates significant p-values.
TABLE 20 Ventricular volumes and function data at follow-up CMR scan
Volumetric variable
Treatment arm
p-value 95% CI of differenceIRA (n= 80) CR (n= 84)
LVMI (g/m2), median (IQR) 43.4 (38.0–49.3) 47.4 (40–52.6) 0.33 –0.04 to 0.14a
LVEDVI (ml/m2), median (IQR) 95.0 (82.7–107) 93.3 (82.2–110) 0.63 –0.03 to 0.02a
LVESVI (ml/m2), median (IQR) 43.6 (34.8–57.9) 45.1 (37.8–58) 0.33 –0.04 to 0.14a
LVEF (%), mean (SD) 50.8 (8.7) 49.7 (9.4) 0.42 –1.6 to 3.9
LVEDVI, LV end-diastolic volume index; LVESVI, LV end-systolic volume index.
a Log10-transformed variable.
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Perfusion analysis
One hundred and fifty-nine patients underwent adenosine and rest myocardial perfusion. Results are
shown in Table 22. Stress-induced perfusion defects were present in 21% of patients in each treatment
arm, with a similar ischaemic burden. Only three patients (two in the IRA arm and one in the CR arm),
who had a subsequent revascularisation after the index procedure, had residual ischaemia; however,
the ischaemic burden in these patients was very small. Twelve patients (six in the IRA arm and six in the
CR arm; p= 0.91) had an ischaemic burden on CMR scan > 20%.
Clinical outcomes
Follow-up
Median follow-up length was 372 days (IRA 378 days vs. CR 366 days; p= 0.37). One hundred and
ninety-eight (98%) patients attended the 12-month clinical follow-up (three patients died before this and
two patients withdrew consent for follow-up at days 7 and 220).
Safety end points
Length of inpatient stay and incidence of in-hospital clinical events were similar in the treatment arms.
There were no adverse effects on safety with CR (Table 23).
TABLE 22 Perfusion analysis
Variable
Treatment arm
p-value 95% CI of differenceIRA (n= 80) CR (n= 84)
Perfusion analysis
Presence of ischaemia, n/N (%) 16/77 (20.8) 17/82 (20.7) 0.99 N/Aa
Ischaemic burden
Median (IQR) 0.0 (0–0) 0.0 (0–0) 0.81 –6.1 to 15.9b
Mean (SD) 4.3 (11.3) 3.4 (8.9) 0.37
In those with ischaemia, mean (SD) 20.4 (17.1) 15.5 (13.7)
Patients, n/N (%) with ischaemic burden > 20% 6/77 (7.8) 6/82 (7.3) 0.91 N/Aa
a Categorical data assessed using chi-squared analysis.
b Non-transformable non-normally distributed variable assessed using Mann–Whitney U-testing.
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The primary clinical outcome of the first combined MACE at 12 months was borderline significantly
reduced in patients undergoing CR (see Table 24 and Figure 13). This was driven primarily by reduced
revascularisation events (4.1% vs. 9.5%; p= 0.13) and recurrent MI (0% vs. 2.9%; p= 0.09). There was
one death in each arm (both cardiovascular) and two-thirds of MIs were type 1 non-STEMI.
Clinical event rates (time to first event) for patients in the CMR imaging substudy versus those who did not
take part are shown in Table 25. There was a higher event rate in non-CMR imaging patients that was
largely driven by an increase in non-cardiovascular mortality and acute stent thrombosis.
TABLE 24 Twelve-month clinical outcomes
Variable
Treatment arm
HR (95% CI) p-valueCR (n= 98) IRA (n= 105)
Time to first event (MACEs)
MACEs, n/N (%) 8/98 (8.2) 18/105 (17.1) 0.43 (0.18 to 1.04) 0.055
All-cause mortality, n/N (%) 1/98 (1.0) 1/105 (1.0) 1.07 (0.07 to 17.4) 0.96
CV mortality 1/98 (1.0) 1/105 (1.0) 1.07 (0.07 to 17.4) 0.96
Non-CV mortality 0/98 (0.0) 0/105 (0.0) a 1.00
Recurrent MI, n/N (%) 0/98 (0.0) 3/105 (2.9) a 0.09
Type 1 0/98 (0.0) 2/105 (1.9) a 0.17
Type 4b (ST) 0/98 (0.0) 1/105 (1.0) a 0.33
Heart failure, n/N (%) 3/98 (3.1) 4/105 (3.8) 0.80 (0.17 to 3.7) 0.77
Repeat revascularisation, n/N (%) 4/98 (4.1) 10/105 (9.5) 0.40 (0.12 to 1.3) 0.13
CV, cardiovascular; ST, stent thrombosis.
a Unable to calculate HR as ≥ 1 treatment arms had no events.
p-values calculated using log-rank test (Cox regression).
TABLE 23 Inpatient events
Safety profile: inpatient clinical events
Treatment arm
OR (95% CI) p-valueIRA (n= 105) CR (n= 98)
Length of inpatient stay (days)
Median (IQR) 3 (2–4) 3 (2–4) 0.13
Mean (SD) 3.9± 2.8 3.5± 2.6
Contrast nephropathy, n/N (%) 0/105 (0.0) 1/98 (1.0) a 0.30
Vascular access injury needing repair, n/N (%) 0/105 (0.0) 0/98 (0.0) a 1.00
Death, n/N (%) 1/105 (0.9) 1/98 (1.0) 1.07 (0.07 to 17.4) 0.96
Recurrent MI, n/N (%) 1/05 (0.9) 0/98 (0.0) a 0.33
CVA/TIA, n/N (%) 0/105 (0.0) 0/98 (0.0) a 1.00
Heart failure, n/N (%) 1/105 (1.0) 2/98 (2.0) 2.17 (0.19 to 24.3) 0.52
Repeat revascularisation, n/N (%) 3/105 (2.9) 2/98 (2.0) 0.71 (0.12 to 4.3) 0.71
Major bleed, n/N (%) 1/105 (1.0) 1/98 (1.0) 1.09 (0.07 to 7.7) 0.90
CVA, cerebrovascular accident; TIA, transient ischaemic attack.
a Unable to calculate OR as ≥1 treatment arms had no events.
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FIGURE 13 Kaplan–Meier survival curves for 12-month clinical outcomes.
TABLE 25 Twelve-month clinical outcomes in CMR imaging substudy vs. non-CMR imaging patients
Variable
CMR imaging
substudy (n= 203)
Non-CMR imaging
substudy (n= 93)
HR (95% CI) (CMR imaging substudy
vs. non-CMR imaging substudy) p-value
Time to first event (MACEs)
MACEs, n/N (%) 26/203 (13.3) 22/93 (23.7) 0.50 (0.27 to 0.93) 0.026
All-cause mortality,
n/N (%)
2/203 (1.0) 6/93 (5.4) 0.14 (0.03 to 0.73) 0.007
CV mortality 2/203 (1.0) 3/93 (3.2) 0.30 (0.05 to 1.82) 0.17
Non-CV mortality 0/203 (0.0) 3/93 (3.2) a 0.03
Recurrent MI, n/N (%) 3/203 (1.5) 4/93 (4.3) 0.33 (0.07 to 1.52) 0.14
Type 1 2/105 (1.0) 1/93 (1.1) 0.92 (0.08 to 10.2) 0.94
Type 4b (ST) 1/203 (0.5) 3/93 (3.2) 0.15 (0.02 to 1.45) 0.06
Heart failure, n/N (%) 7/203 (3.5) 5/93 (5.4) 0.63 (0.19 to 2.04) 0.44
Repeat revascularisation,
n/N (%)
14/203 (7.0) 7/93 (7.5) 0.97 (0.39 to 2.5) 0.98
CV, cardiovascular; ST, stent thrombosis.
a Unable to calculate OR as ≥ 1 treatment arms had no events.
DOI: 10.3310/eme03010 EFFICACY AND MECHANISM EVALUATION 2016 VOL. 3 NO. 1
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McCann et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47

Chapter 5 Discussion
This is the first detailed study of acute and follow-up CMR imaging outcomes in a randomised study ofIRA only versus CR in patients with multivessel coronary disease at the PPCI. The data have confirmed
that non-IRA PCI is associated with additional (type 4a) infarctions. However, these type 4a MIs are
relatively infrequent, generally small and did not result in an increase in total IS.81 There is mounting
evidence from randomised trials that treating multivessel disease with CR leads to a reduction in MACEs
after the PPCI than with an IRA-only strategy.19,80 The current results provide reassurance that CR does not
lead to increased total IS or reduced myocardial salvage.
The patients in the substudy had similar baseline characteristics to those in the main trial. Time to
revascularisation82 and anterior MI83,84 are strongly associated with IS and, therefore, randomisation was
stratified by these variables. The clinical event rates in CMR imaging participants was inevitably lower than
that in those not participating in the CMR imaging substudy, largely because of the fact that some patients
died or were too ill to take part. However, there was a similar reduction in the HR for MACEs in the CR
CMR imaging subgroup as that seen in the main study compared with IRA-only revascularisation. These
findings lead us to believe that there was no systematic bias in more sick patients in the IRA-only arm not
participating in the CMR imaging substudy.
It is well recognised that elective PCI can cause a rise in troponin levels is approximately 30% of patients
and in approximately 50% undergoing PCI for unstable angina.24 Such type 4a MI81 can be detected on
CMR scans and have been associated with adverse prognosis.27 In this substudy of the CvLPRIT, the
prevalence of > 1 CMR imaging-detected infarct in patients receiving CR was double that in the IRA-only
arm (23.8% vs. 11.2% respectively), and more than threefold for the acute non-IRA infarcts (17.1% CR vs.
4.8% IRA only). Previous Q-wave MI was an exclusion criterion in this study, but 4% of the CR group and
3% in the IRA-only group had a history of previous non-STEMI. These data suggest that for 100 patients
with multivessel disease who were randomised to receive CR at the time of the PPCI, 12% will have
evidence of additional CMR imaging-detectable infarctions compared with IRA-only revascularisation.
However, this proportion is less than that might have been expected from previous studies in elective
PCI.24,27 The extent of acute non-IRA infarction was generally small (median 2.5% of LVM). Importantly,
total IS was not increased at baseline or at follow-up, and there were no significant differences in LV
volumes or ejection fraction between the treatment groups. Peak CK was also similar in the two groups.
The mean IS was slightly lower than expected. This finding means that the power of the study to detect a
4% difference in IS was reduced. This is most likely because of the use of the FWHM technique to quantify
IS, which gives lower ISs than commonly used thresholding techniques.85,86
These findings confirm that the non-IRA intervention at the time of the PPCI does not lead to increased
total IS. In the main CvLPRIT,80 CR resulted in a significantly reduced HR for the 12-month combined
MACEs, despite the greater prevalence of CMR imaging-detected type 4a MI shown in the current results.
There are limited data on whether or not revascularisation-induced myocardial injury detected by CMR
imaging is linked to prognosis27 and no data in patients presenting with STEMI. In an observational study
of 152 patients undergoing elective revascularisation, 32% had evidence of new LGE which averaged 5 g
(≈4% of LVM), but half of these patients were treated with a CABG.27 In that study, patients with new
infarction following revascularisation had reduced ejection fraction, increased LV volumes, increased total
IS and a threefold increase in MACEs at a median of 2.9 years’ follow-up compared with those without
new LGE.27 Although it cannot be completely discounted, given that the CR group in the current study
group had no increase in total IS, LV volumes or reduced ejection fraction, it seems unlikely that the
short- to medium-term clinical benefits of CR will be offset in the long term by increased heart failure or
sudden cardiac deaths.19,80 Long-term follow-up of the CvLPRIT patients will help answer this question, but
larger studies are also needed to provide further reassurance on the safety of a CR strategy at the time of
the PPCI.
DOI: 10.3310/eme03010 EFFICACY AND MECHANISM EVALUATION 2016 VOL. 3 NO. 1
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McCann et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
49
No significant differences in myocardial salvage were observed between the treatment groups in this study.
There was a trend for the AAR to be higher in IRA-only arm and it is a limitation that a large proportion of
the patients did not have discernible oedema on T2W-STIR despite good image quality. This does reduce
the power to detect differences in myocardial salvage between the treatment arms. Adjusting the primary
outcome for AAR did not alter the conclusions. Additionally, as for IS, the fact that there was also no
difference in LV volumes or ejection fraction makes it unlikely that this would have been significant
with increased sample size. Non-IRA revascularisation at the time of the PPCI could increase perfusion
by relieving flow-limiting stenoses to watershed areas resulting in increased myocardial salvage.29
Alternatively, resting myocardial perfusion and flow reserve following PCI may actually be reduced, as has
been shown in elective patients as a result of distal embolisation, particularly when the PCI is associated
with new LGE.28,29
Unexpectedly, we also observed no difference in ischaemic burden between the groups undergoing
follow-up stress perfusion CMR imaging. There are several potential explanations for this finding. First, it is
well recognised that even severe angiographic stenoses may not cause ischaemia.87,88 Second, 11 patients
in the IRA-only arm had further PCI before the stress CMR imaging, which is likely to have reduced
ischaemic burden in this group. Third, the small number of crossovers from randomisation is likely to have
diminished the differences in ischaemia between the groups. Finally, the stress CMR imaging was
undertaken in patients on optimal medical therapy, which may dramatically reduce post-MI ischaemia30
making it more difficult to detect differences between the groups. This fact may also explain why the
overall ischaemic burden in our study was small (3–4%) and is consistent with the MPS results that did not
demonstrate any patients to have an ischaemic burden > 20%.80 These results challenge the assumption
that ischaemia is the major driver of adverse clinical events following STEMI30 for which there is an absence
of data in the modern PPCI era. Although the numbers are small, we did see a trend to a reduction in
spontaneous MI in the CR group, so plaque pacification may be one mechanism that contributes to the
reduction in MACEs with CR.
Limitations
Seven patients died or were too ill to enter the CMR imaging substudy and inevitably the clinical event rate
was lower in CMR imaging participants than the main study that was driven by non-cardiovascular death
and recurrent MI. However, it is felt that it is unlikely any bias has arisen given the very similar reduction in
HR in the CMR imaging substudy to the main trial. IS was lower than expected and this has decreased the
power of the study to detect a 4% difference between treatment groups, The optimal timing to assess
CMR imaging IS post STEMI is uncertain.89 An early time point was chosen to enhance participation in the
CMR imaging substudy as it was felt there could have been a higher dropout rate scanning patients after
discharge from hospital. Finally, MSI was only reliably measured in ≈75% of patients and the use of novel
T1 or T2 mapping techniques for future studies may lead to a more robust assessment. Longer-term
follow-up of participants is required to assess whether or not the small increase in non-IRA MI seen with
CR is clinically significant. Thirty patients in the CMR imaging substudy underwent a staged non-IRA PCI.
As these numbers are small and the patients were not randomised it cannot be stated whether CR at the
index procedure or staged during initial hospitalisation results in the same myocardial injury.
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Chapter 6 Conclusions
An in-hospital CR strategy in patients with multivessel disease at the time of the PPCI does not lead toincreased total IS compared with an IRA-only strategy, but is associated with a small increase in type 4a
MI in non-IRA territories. These findings provide further reassurance that non-IRA intervention can be
considered at the time of the PPCI, but larger studies with long-term follow-up data for safety are required.
Recommendations for research
Larger clinical trials with longer follow-up in patients with multivessel disease presenting for the PPCI are
required to assess (1) whether or not death and MI are reduced by a CR strategy (this is particularly
important given the findings of the current study, which have confirmed that CR is associated with a small
increase in non-IRA MI); (2) whether or not functional assessment of non-IRA lesions results in similar
outcomes to a pragmatic angiographic-based revascularisation strategy; (3) the optimal timing of in-hospital
versus staged outpatient CR; and (4) the cost-effectiveness of various CR strategies (immediate, staged
and FFR guided) versus an IRA-only strategy. Additionally, long-term follow-up of participants in the
CvLPRIT-CMR imaging substudy is required to assess whether or not the small increase in non-IRA MI seen
with CR is clinically significant.
Summary
The CvLPRIT-CMR imaging included 203 patients with inpatient CMR scans after being randomised to
either a CR strategy (n= 98) or an IRA-only strategy (n= 105) for the treatment of multivessel disease at
the time of the PPCI. A small, but statistically significant, increase in non-IRA infarction was detected in the
CR group, but the primary outcome of IS as a proportion of the LVM was not significantly different with
the two treatment strategies. There were no differences in MVO, LV volumes, ejection fraction or MSI
between the groups. These data provide reassurance that in-hospital non-IRA related revascularisation
does not lead to an increase in total IS in patients undergoing the PPCI for STEMI.
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Appendix 1 Assent form
VERBAL ASSENT SHEET TO INVITE PARTICIPATION IN THE CVLPRIT STUDY 
“Complete Versus Lesion only Primary PCI Trial” 
 
Version 6 (30th October 2010) 
This should be read to the patients and the result of the discussion documented in the 
clinical notes 
 
• Your doctors have diagnosed that you are having a heart attack, which means that it is likely 
one of the arteries in your heart is blocked reducing blood supply to your heart muscle. 
• In this hospital the usual treatment is to open the blocked artery with a balloon and stent using 
a procedure called angiography in which a fine tube is passed into the heart. 
• Sometimes more than one artery is blocked or narrowed.  At the moment we do not know if 
you have only one blocked artery causing your heart attack, or you have another one which is 
narrowed or blocked. 
• We are undertaking a research study to try and find out whether it is better to treat just the 
artery causing the heart attack (which is a routine approach in many centres), or to treat all the 
arteries that look narrowed or blocked at the same time. 
• The title of the study is CVLPRIT (Complete Versus Lesion only Primary PCI Trial).  If we 
find that you have more than one artery narrowed or blocked, we would like to invite you to 
take part in the study. 
• If you agree, we will either treat only the blocked artery causing the heart attack or we will 
attempt to open all the affected arteries.  
• Allocation to single artery or multiple artery treatment will be performed at random (rather 
like tossing a coin to make the comparison fair) as we do not know which treatment is better. 
• We are also asking for your permission to record simple details of your health condition and 
treatments in our confidential research record as part of a “registry”.  
• After you have had your early treatment and are recovering, we will provide you with further 
information about the study and you will have another opportunity to discuss this and decide 
if you wish to carry on in the study or not. 
Whether you decide to take part or not is entirely up to you, and in any case you will receive the best 
care we can provide for your condition. 
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Appendix 2 Clinical outcome definitions
Contrast-induced nephropathy
A rise in creatinine levels of > 25% or 44.2 µmol/l within 48 hours after angiography and persisting for at
least 48 hours.
Death
Death from any cause classified as cardiovascular or non-cardiovascular.
Causes of cardiovascular deaths include, but are not limited to, deaths resulting from atherosclerotic
vascular disease (excluding coronary), congestive heart failure, cardiogenic shock, during or immediately
following a CABG procedure, during or immediately following a PCI procedure, dysrhythmia, pulmonary
embolism, MI, sudden cardiac death, intracranial haemorrhage, non-haemorrhagic stroke and other
cardiovascular causes. Cardiovascular death includes any cardiac causes, or other vascular causes
(e.g. pulmonary embolism, aortic dissection).
Non-cardiovascular death includes accidental death, trauma, haemorrhage (not intracranial), infection,
malignancy, suicide and other.
Myocardial infarction (new)
Hospital admission (or in hospital) with:
l Type 1: spontaneous re-MI: recurrent angina symptoms or new ECG changes occurring before PCI or
< 48 hours from PCI that is compatible with re-MI associated with an elevation of creatine kinase MB
isoenzyme (CK-MB), troponin, or total CK levels beyond the upper limit of normal (ULN) and 20% or
more above the previous value.
l Type 4b: stent thrombosis documented by coronary angiography and/or autopsy AND fulfilling the
criteria of spontaneous MI (type 1).
l Type 4a: CK-MB or total CK levels more than three times the ULN within 48 hours following PCI.
If the pre-PCI CK-MB or total CK level is higher than the ULN, there also needs to be:
¢ either the demonstration of a falling CK-MB or total CK level prior to the onset of the
suspected event
¢ or a subsequent peak of the cardiac biomarker of at least 20% above the previous value obtained
prior to the onset of the suspected event
¢ with either an appropriate clinical presentation or new ischaemic ECG changes (ST-segment
depression or ST-segment elevation or development of new pathological Q-waves/LBBB).
Transient ischaemic attack/cerebrovascular event
Defined as the presence of a new focal neurological deficit thought to be vascular in origin with signs or
symptoms lasting more than 24 hours. It is strongly recommended (but not required) that an imaging
procedure, such as a computed tomography scan or MRI, be performed. Stroke will be further classified as
ischaemic, haemorrhagic or type uncertain.
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Major bleed
l Cumulative occurrence of intracranial or intraocular bleeding.
l Haemorrhage at the vascular access site requiring intervention.
l Reduction in haemoglobin levels of at least 5 g/dl.
l Reoperation for bleeding or transfusion of a blood product (at least 2 units).
l Bleeding causing substantial hypotension requiring the use of inotropic agents.
l All other bleeding events were considered as minor (i.e. epistaxis, blood traces in the stool, etc.).
Planned or repeat coronary artery bypass graft or percutaneous
coronary intervention
l IRA target lesion re-interventions (TLRs) inside the implanted stent or within 5-mm proximally or distally
or repeated interventions in the same vessel (target vessel revascularisation; TVR) PCIs or by
CABG surgery.
l Non-IRA TVR.
l IRA TLR (i.e. lesions within the index IRA, but not the IRA culprit lesion).
l Non-IRA TLR.
l PCI to lesions not identified previously.
l CABG for new symptoms or complications of PCI. Discussions in a cardiosurgical multidisciplinary team
(MDT) forum must be recorded (MDT yes/no with result of discussion).
Heart failure
Any hospital admission with any of the following symptoms and signs:
l worsening breathlessness
l fatigue
l fluid overload
l pulmonary oedema
l elevated venous pressure
l elevated B-type natriuretic peptide levels.
Confirmation of heart failure according to local expert judgement and evidence of impaired LV function
will be required for the event to be classified as heart failure.
Other serious adverse events
Any event requiring hospitalisation or prolonging length of stay during hospitalisation at time of
index procedure.
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Appendix 3 Cardiac magnetic imaging scans
database lock
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Appendix 4 Data and Safety Monitoring Board
interim report
DOI: 10.3310/eme03010 EFFICACY AND MECHANISM EVALUATION 2016 VOL. 3 NO. 1
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McCann et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
71


Part of the NIHR Journals Library 
www.journalslibrary.nihr.ac.uk
Published by the NIHR Journals Library
This report presents independent research funded by the 
National Institute for Health Research (NIHR). The views 
expressed are those of the author(s) and not necessarily 
those of the NHS, the NIHR or the Department of Health
EME
HS&DR
HTA
PGfAR
PHR
